propranolol has been researched along with Hemangioma, Capillary in 203 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Hemangioma, Capillary: A dull red, firm, dome-shaped hemangioma, sharply demarcated from surrounding skin, usually located on the head and neck, which grows rapidly and generally undergoes regression and involution without scarring. It is caused by proliferation of immature capillary vessels in active stroma, and is usually present at birth or occurs within the first two or three months of life. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although propranolol has been established as the gold standard when treatment is sought for infantile hemangioma, concerns over its side effect profile have led to increasing usage of atenolol, a beta-1 selective blocker." | 9.41 | Should Propranolol Remain the Gold Standard for Treatment of Infantile Hemangioma? A Systematic Review and Meta-Analysis of Propranolol Versus Atenolol. ( Carroll, W; Chen, T; Clemmens, C; Gudipudi, R; Nguyen, SA, 2023) |
| "The purpose of this study was to compare long-term neurocognitive functioning (working memory, processing speed, and attention) between children who had been treated with either propranolol or atenolol for infantile hemangioma during infancy." | 8.31 | Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma. ( Breugem, CC; Breur, JMPJ; de Graaf, M; de Laat, PCJ; de Wildt, SN; Hermans, MM; Langeveld, HR; Mendels, EJ; Pasmans, SGMA; Raphael, MF; Rietman, AB; Schappin, R, 2023) |
| "The distribution and response to propranolol of problematic facial infantile haemangiomas (IHs) has rarely been described in the literature." | 8.31 | Distribution of problematic localized facial infantile haemangiomas and their response to propranolol: a retrospective cohort study. ( Chang, L; Chang, SJ; Chen, J; Chen, Q; Gao, W; Li, H; Lin, X; Qiu, Y; Yu, Z; Zhou, L, 2023) |
| "Although the efficacy of propranolol in the treatment of infantile hemangioma (IH) has been well established, clinical data on the safety and tolerability of propranolol in neonates are still lacking." | 8.31 | Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population. ( Bai, H; Cheng, J; Fu, R; Huan, X; Huang, M; Jin, P; Wu, Z; Yuan, H; Zou, Y, 2023) |
| "Propranolol, a non-selective blocker of the β-adrenoceptor (AR), is a first-line treatment for infantile hemangioma (IH)." | 8.12 | Propranolol inhibits the angiogenic capacity of hemangioma endothelia via blocking β-adrenoceptor in mast cell. ( Dong, C; Dong, K; Dou, L; Gao, W; He, L; Li, J; Li, K; Lu, W; Song, W; Wang, L; Xia, C; Ye, Y; Zhong, H, 2022) |
| "For infantile hemangiomas (IH) requiring treatment, including those in high-risk locations or in the setting of ulceration, oral propranolol is first-line therapy." | 8.12 | Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol. ( Boull, C; Maguiness, S; Meyer-Mueller, C; Nicholson, C; Polcari, I, 2022) |
| "We report three infants with infantile hemangioma who experienced severe agitation and diarrhea following propranolol administration." | 8.12 | Propranolol therapy for hemangiomas in infants with neonatal abstinence syndrome may produce intolerable side effects. ( Chen, A; Poffenberger, P; Twist, J; Zinn, Z, 2022) |
| "Propranolol is used to treat problematic infantile hemangiomas (IHs), but its safety in infants <5 weeks corrected age has not been established." | 8.12 | Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age. ( Check, JF; Gatts, JE; McLean, TW; Rush, MC; Samelak, DM, 2022) |
| "Infantile haemangiomas are common benign tumours of infancy, which can be treated effectively with beta-blockers such as propranolol and atenolol." | 8.12 | Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma. ( Breugem, CC; Breur, JMPJ; De Graaf, M; De Laat, PCJ; De Wildt, SN; Hermans, MM; Jonge Poerink, E; Langeveld, HR; Mendels, EJ; Pasmans, SGMA; Ragamin, A; Raphael, MF; Rietman, AB; Schappin, R, 2022) |
| "Oral propranolol is recommended as the first-line agent for infantile hemangioma requiring systemic treatment." | 8.12 | Efficacy of intravenous propranolol for life-threatening diffuse neonatal hemangiomatosis. ( Ishikawa, T; Seki, K; Uchiyama, H, 2022) |
| "To assess the efficacy of transcatheter arterial embolization (TAE) plus propranolol treatment for infantile hepatic hemangioma (IHH)." | 8.12 | Clinical evaluation of transcatheter arterial embolization combined with propranolol orally treatment of infantile hepatic hemangioma. ( Guo, L; Li, J; Song, D; Wang, L, 2022) |
| "In recent years propranolol has become the treatment of choice for infantile hemangiomas (IHs)." | 7.83 | Is Routine Electrocardiography Necessary Before Initiation of Propranolol for Treatment of Infantile Hemangiomas? ( Krol, AL; Leitenberger, SL; MacArthur, CJ; Mann, JA; Tollefson, MM; Yarbrough, KB, 2016) |
| "Propranolol seemed to be effective for treatment of hemangiomas in children and adolescents, and not just in the proliferative stage, with responses in almost all the patients." | 7.80 | Treatment of children and adolescents with hemangioma using propranolol: preliminary results from a retrospective study. ( Albuquerque, JC; Bastos, MV; Felix, FH; Félix, JA; Fontenele, JB; Magalhães, RA; Trompieri, NM, 2014) |
| "A 33-day-old female with an ulcerated infantile hemangioma (IH) undergoing oral therapy with propranolol 2 mg/kg per day developed hyperkalemia and hyperphosphatemia 24 h after starting medication." | 7.78 | Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding? ( Buffon, RB; Cavalli, R; Colli, AM; de Souza, M; Gelmetti, C, 2012) |
| "Infants can benefit from a rapid, meaningful reduction in periocular capillary hemangioma-induced astigmatism following oral propranolol treatment." | 7.77 | Reduction in astigmatism using propranolol as first-line therapy for periocular capillary hemangioma. ( Ben-Zion, I; Fabian, ID; Samuel, C; Spierer, A, 2011) |
| "Infantile hemangioma is one of the most common benign tumors of infancy." | 6.72 | Propranolol treatment of infantile subglottic hemangioma: a report of two cases and a literature review. ( Ganeva, K; Nikiforova, L; Sapundzhiev, N; Shivachev, P, 2021) |
| "Propranolol treatment mostly leads to regression of hemangiomas with satisfactory aesthetic results, but unfortunately not in all cases." | 5.91 | Nd:YAG 1064-nm laser for residual infantile hemangioma after propranolol treatment. ( Avitan-Hersh, E; Khamaysi, Z; Pam, N; Zaaroura, H, 2023) |
| "Oral propranolol has not been shown to impact physical development, such as weight and height." | 5.91 | The impact of propranolol on the growth and development of children with proliferative infantile hemangioma during treatment. ( Chen, S; Chen, X; Deng, L; Gao, J; Huang, L; Lin, X; Liu, C; Wang, Q; Wang, T, 2023) |
| "Propranolol was successfully tapered over 3 weeks by reducing the dose by 50% weekly until it reached the therapeutic dose." | 5.91 | Excessively High Chronic Propranolol Overdose in Infantile Hemangioma: A Case Report. ( Alessa, A; Alghanem, A; Alhammad, AM; Alshammari, H; Elsharawy, Y, 2023) |
| " Adverse event and drug-related adverse event rates were 87." | 5.72 | Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study. ( Hakamata, A; Hayano, S; Inui, N; Iwashima, S; Kashiwagura, Y; Nagata, E; Nishida, M; Odagiri, K; Okada, E; Sano, S; Tanaka, S; Uchida, S; Umemura, K; Watanabe, H, 2022) |
| "Propranolol is a safe, effective and well-tolerated treatment in Australian children with IH." | 5.72 | Immediate possible adverse event rates in infants treated with oral propranolol for infantile haemangiomas at an Australian urban tertiary hospital between 2016 and 2019. ( Adams, L; Ryan, E, 2022) |
| "Severe hypoglycemia was common in infants aged >1 year, when PPL was used for ≥6 months." | 5.72 | Severe hypoglycemia in propranolol treatment for infantile hemangiomas. ( Baba, N; Kaneko, T; Kuwano, Y; Morimoto, A; Ozeki, M; Sasaki, S, 2022) |
| "Infantile hemangiomas are the most common benign vascular tumors in childhood." | 5.56 | Propranolol-resistant infantile hemangioma successfully treated with sirolimus. ( Baselga, E; Dávila-Osorio, VL; Iznardo, H; Puig, L; Roé, E, 2020) |
| "Although propranolol has been established as the gold standard when treatment is sought for infantile hemangioma, concerns over its side effect profile have led to increasing usage of atenolol, a beta-1 selective blocker." | 5.41 | Should Propranolol Remain the Gold Standard for Treatment of Infantile Hemangioma? A Systematic Review and Meta-Analysis of Propranolol Versus Atenolol. ( Carroll, W; Chen, T; Clemmens, C; Gudipudi, R; Nguyen, SA, 2023) |
| "Kaposiform hemangioendothelioma is a rare vascular tumor in children." | 5.37 | Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment. ( de Blaauw, I; Hermans, DJ; Kool, LJ; van Beynum, IM; van der Vijver, RJ; van der Vleuten, CJ, 2011) |
| "The purpose of this study was to compare long-term neurocognitive functioning (working memory, processing speed, and attention) between children who had been treated with either propranolol or atenolol for infantile hemangioma during infancy." | 4.31 | Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma. ( Breugem, CC; Breur, JMPJ; de Graaf, M; de Laat, PCJ; de Wildt, SN; Hermans, MM; Langeveld, HR; Mendels, EJ; Pasmans, SGMA; Raphael, MF; Rietman, AB; Schappin, R, 2023) |
| "The distribution and response to propranolol of problematic facial infantile haemangiomas (IHs) has rarely been described in the literature." | 4.31 | Distribution of problematic localized facial infantile haemangiomas and their response to propranolol: a retrospective cohort study. ( Chang, L; Chang, SJ; Chen, J; Chen, Q; Gao, W; Li, H; Lin, X; Qiu, Y; Yu, Z; Zhou, L, 2023) |
| "Although the efficacy of propranolol in the treatment of infantile hemangioma (IH) has been well established, clinical data on the safety and tolerability of propranolol in neonates are still lacking." | 4.31 | Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population. ( Bai, H; Cheng, J; Fu, R; Huan, X; Huang, M; Jin, P; Wu, Z; Yuan, H; Zou, Y, 2023) |
| "Propranolol, a non-selective blocker of the β-adrenoceptor (AR), is a first-line treatment for infantile hemangioma (IH)." | 4.12 | Propranolol inhibits the angiogenic capacity of hemangioma endothelia via blocking β-adrenoceptor in mast cell. ( Dong, C; Dong, K; Dou, L; Gao, W; He, L; Li, J; Li, K; Lu, W; Song, W; Wang, L; Xia, C; Ye, Y; Zhong, H, 2022) |
| "For infantile hemangiomas (IH) requiring treatment, including those in high-risk locations or in the setting of ulceration, oral propranolol is first-line therapy." | 4.12 | Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol. ( Boull, C; Maguiness, S; Meyer-Mueller, C; Nicholson, C; Polcari, I, 2022) |
| "We report three infants with infantile hemangioma who experienced severe agitation and diarrhea following propranolol administration." | 4.12 | Propranolol therapy for hemangiomas in infants with neonatal abstinence syndrome may produce intolerable side effects. ( Chen, A; Poffenberger, P; Twist, J; Zinn, Z, 2022) |
| "Propranolol is used to treat problematic infantile hemangiomas (IHs), but its safety in infants <5 weeks corrected age has not been established." | 4.12 | Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age. ( Check, JF; Gatts, JE; McLean, TW; Rush, MC; Samelak, DM, 2022) |
| "Infantile haemangiomas are common benign tumours of infancy, which can be treated effectively with beta-blockers such as propranolol and atenolol." | 4.12 | Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma. ( Breugem, CC; Breur, JMPJ; De Graaf, M; De Laat, PCJ; De Wildt, SN; Hermans, MM; Jonge Poerink, E; Langeveld, HR; Mendels, EJ; Pasmans, SGMA; Ragamin, A; Raphael, MF; Rietman, AB; Schappin, R, 2022) |
| "Oral propranolol is recommended as the first-line agent for infantile hemangioma requiring systemic treatment." | 4.12 | Efficacy of intravenous propranolol for life-threatening diffuse neonatal hemangiomatosis. ( Ishikawa, T; Seki, K; Uchiyama, H, 2022) |
| "To assess the efficacy of transcatheter arterial embolization (TAE) plus propranolol treatment for infantile hepatic hemangioma (IHH)." | 4.12 | Clinical evaluation of transcatheter arterial embolization combined with propranolol orally treatment of infantile hepatic hemangioma. ( Guo, L; Li, J; Song, D; Wang, L, 2022) |
| "Propranolol-induced involution is a unique biological feature of some pediatric vascular tumors, for instance infantile hemangioma (IH), cerebral cavernoma or chorioangioma." | 3.83 | The embryo-placental CD15-positive "vasculogenic zones" as a source of propranolol-sensitive pediatric vascular tumors. ( Anspach, L; Roth, W; Seidmann, L, 2016) |
| "Cervicofacial segmental infantile hemangiomas (IH) may result in airway obstruction requiring use of propranolol to induce hemangioma regression and reestablish the airway." | 3.83 | Use of intravenous propranolol for control of a large cervicofacial hemangioma in a critically ill neonate. ( Fernando, SJ; Krol, A; Leitenberger, S; MacArthur, CJ; Majerus, M, 2016) |
| "In recent years propranolol has become the treatment of choice for infantile hemangiomas (IHs)." | 3.83 | Is Routine Electrocardiography Necessary Before Initiation of Propranolol for Treatment of Infantile Hemangiomas? ( Krol, AL; Leitenberger, SL; MacArthur, CJ; Mann, JA; Tollefson, MM; Yarbrough, KB, 2016) |
| "Propranolol seemed to be effective for treatment of hemangiomas in children and adolescents, and not just in the proliferative stage, with responses in almost all the patients." | 3.80 | Treatment of children and adolescents with hemangioma using propranolol: preliminary results from a retrospective study. ( Albuquerque, JC; Bastos, MV; Felix, FH; Félix, JA; Fontenele, JB; Magalhães, RA; Trompieri, NM, 2014) |
| "A 33-day-old female with an ulcerated infantile hemangioma (IH) undergoing oral therapy with propranolol 2 mg/kg per day developed hyperkalemia and hyperphosphatemia 24 h after starting medication." | 3.78 | Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding? ( Buffon, RB; Cavalli, R; Colli, AM; de Souza, M; Gelmetti, C, 2012) |
| "Infants can benefit from a rapid, meaningful reduction in periocular capillary hemangioma-induced astigmatism following oral propranolol treatment." | 3.77 | Reduction in astigmatism using propranolol as first-line therapy for periocular capillary hemangioma. ( Ben-Zion, I; Fabian, ID; Samuel, C; Spierer, A, 2011) |
| " We observed no serious adverse events." | 3.11 | Efficacy and Safety of Propranolol Gel for Infantile Hemangioma: A Randomized, Double-Blind Study. ( Hanawa, M; Ishii, I; Kawasaki, Y; Mitsukawa, N; Rikihisa, N; Shiko, Y; Suzuki, T; Takatsuka, H, 2022) |
| " However, other less lipophilic β-blockers, such as nadolol, may be preferable in individuals who experience propranolol unresponsiveness or adverse events." | 3.11 | Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial. ( Drolet, B; Kanigsberg, N; Lara-Corrales, I; Liy-Wong, C; Ma, J; Pope, E; Sibbald, C, 2022) |
| "Propranolol has become the first-line therapy for problematic infantile hemangiomas (IHs) that require systemic therapy." | 3.01 | Efficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial. ( Chen, S; Dai, S; Ji, Y; Jiang, X; Kong, F; Li, L; Lu, G; Qiu, L; Qiu, T; Xiang, B; Yang, K; Zhang, X; Zhang, Y; Zhou, J, 2021) |
| " The incidence of adverse events (AE) and drug-related AE was 97% and 31%, respectively." | 2.84 | Efficacy and safety of oral propranolol for infantile hemangioma in Japan. ( Baba, N; Hayashi, N; Higuchi, T; Kakazu, M; Kaneko, T; Kato, R; Kishi, K; Koh, K; Kuwano, Y; Matsui, K; Morimoto, A; Nakano, A; Ohjimi, H; Ohki, K; Oyama, T; Sasaki, S; Sato, A; Tamaki, Z, 2017) |
| " As an outpatient therapy, propranolol was found to be safe for Chinese children and to have minor side effects." | 2.82 | Is Propranolol Safe and Effective for Outpatient Use for Infantile Hemangioma? A Prospective Study of 679 Cases From One Center in China. ( Chang, L; Chen, H; Jin, Y; Lin, X; Lv, D; Ma, G; Qiu, Y; Wang, T; Yang, X; Ye, X; Yu, W, 2016) |
| "Atenolol is a cardioselective beta-blocker that may have fewer adverse events." | 2.79 | Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. ( Ábarzúa-Araya, A; Heusser, F; Navarrete-Dechent, CP; Retamal, J; Zegpi-Trueba, MS, 2014) |
| "Infantile hemangioma is one of the most common benign tumors of infancy." | 2.72 | Propranolol treatment of infantile subglottic hemangioma: a report of two cases and a literature review. ( Ganeva, K; Nikiforova, L; Sapundzhiev, N; Shivachev, P, 2021) |
| " Parents wary of long-term use and side effects consult plastic surgeons on surgical options or as a second opinion." | 2.72 | Propranolol Therapy in Infantile Hemangioma: It Is Not Just About the Beta. ( England, RW; Lee, JC; Modiri, O; Shawber, CJ; Wu, JK, 2021) |
| " Propranolol can commence for most infants in the outpatient setting and the most frequently employed dosing regimen is 1 mg/kg twice daily." | 2.72 | Infantile hemangioma. Part 2: Management. ( Rodríguez Bandera, AL; Sebaratnam, DF; Wargon, O; Wong, LF, 2021) |
| " The comparison between topical propranolol and oral propranolol led to no discovery of significant difference in the incidence of adverse effects (OR = 1." | 2.66 | The effectiveness and safety of topical β-receptor blocker in treating superficial infantile haemangiomas: A meta-analysis including 20 studies. ( Li, H; Lin, Z; Yu, Z; Zhang, B, 2020) |
| " We included trials comparingdifferent treatments and reported response or adverse events rate in IH patients." | 2.66 | The efficacy and safety of treatments for infantile hemangiomas: a Bayesian network meta-analysis. ( Chen, JJ; Guo, XD; Hu, DL; Shu, Q; Wu, XJ; Xu, S; Xuan, XX; Yang, H; Zhang, H, 2020) |
| "To evaluate the medical literature on the use of β-blockers, through different routes, for the treatment of periorbital infantile hemangiomas and to summarize the recommendations available on dosage and monitoring." | 2.61 | β-blockers in the treatment of periocular infantile hemangioma. ( Al-Haddad, C; El Moussawi, Z; El Salloukh, NA, 2019) |
| " As per the guideline, a preliminary paediatric assessment was performed and a 1 mg/kg test dose was administered, followed by definitive treatment at a dosage of 2 mg/kg in three divided doses." | 2.61 | Orbital infantile haemangioma: radiological features and treatment - case series and literature review. ( Albanese, G; Mohandas, P; Ravenscroft, J; Srinivasan, J; Tambe, K; Taylor, T; Thomas, S; Wells, L, 2019) |
| " Additional research may confirm the best dosage and route of administration to maximize efficacy in reducing induced astigmatism and amblyopia associated with periocular hemangiomas while minimizing side effects." | 2.61 | The Use of β-Blockers for the Treatment of Periocular Hemangiomas in Infants: A Report by the American Academy of Ophthalmology. ( Galvin, JA; Hutchinson, AK; Kraker, RT; Lambert, SR; Pineles, SL; VanderVeen, DK; Wilson, LB, 2019) |
| "A number of clinical trials evaluated the efficacy and adverse effects of oral propranolol in the treatment of infantile hemangioma (IH), but the treatment has not yet been standardized." | 2.61 | Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies. ( Guo, XD; Hu, DL; Shu, Q; Yang, H, 2019) |
| "Fetal brain tumors are rare." | 2.53 | A case of giant fetal intracranial capillary hemangioma cured with propranolol. ( Campos, HG; Cavalheiro, S; Silva da Costa, MD, 2016) |
| "Our observations show that gradually increasing the dosage of propranolol up to 3 mg/kg and gradually weaning the dosage is safe and effective in treatment of problematic IH." | 2.50 | Treatment of problematic infantile hemangiomas with propranolol: a series of 40 cases and review of the literature. ( Dębek, W; Dzienis-Koronkiewicz, E; Hermanowicz, A; Matuszczak, E; Oksiuta, M; Tylicka, M, 2014) |
| "Propranolol treatment (2." | 2.49 | Propranolol treatment in life-threatening airway hemangiomas: a case series and review of literature. ( Broeks, IJ; Dassel, AC; Hermans, DJ; van Beynum, IM; van der Vleuten, CJ, 2013) |
| "Congenital or atypical nevi of the child benefit from genetic progress or improvement of clinical knowledge." | 2.49 | [What’s new in pediatric dermatology?]. ( Lacour, JP, 2013) |
| "Propranolol has recently been reported to be an effective and safe alternative." | 2.47 | The use of propranolol in the management of periocular capillary haemangioma--a systematic review. ( Reddy, AR; Spiteri Cornish, K, 2011) |
| "Propranolol treatment mostly leads to regression of hemangiomas with satisfactory aesthetic results, but unfortunately not in all cases." | 1.91 | Nd:YAG 1064-nm laser for residual infantile hemangioma after propranolol treatment. ( Avitan-Hersh, E; Khamaysi, Z; Pam, N; Zaaroura, H, 2023) |
| " A propranolol dosage level of less than 3 mg/kg/day protected against early relapse [OR = 0." | 1.91 | Factors associated with early relapse of infantile haemangioma in children treated for at least six months with oral propranolol: A case-control study using the 2014-2021 French Ouest DataHub. ( Abasq, C; Adamski, H; Barbarot, S; Beuchée, A; Bouzillé, G; Chrétien, JM; Descatha, A; Droitcourt, C; Dupuy, A; Goronflot, T; Gourraud, PA; Happe, A; Herbert, J; Martin, L; Maruani, A; Mauguen, C; Oger, E, 2023) |
| "Oral propranolol has not been shown to impact physical development, such as weight and height." | 1.91 | The impact of propranolol on the growth and development of children with proliferative infantile hemangioma during treatment. ( Chen, S; Chen, X; Deng, L; Gao, J; Huang, L; Lin, X; Liu, C; Wang, Q; Wang, T, 2023) |
| "Propranolol was successfully tapered over 3 weeks by reducing the dose by 50% weekly until it reached the therapeutic dose." | 1.91 | Excessively High Chronic Propranolol Overdose in Infantile Hemangioma: A Case Report. ( Alessa, A; Alghanem, A; Alhammad, AM; Alshammari, H; Elsharawy, Y, 2023) |
| " Adverse event and drug-related adverse event rates were 87." | 1.72 | Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study. ( Hakamata, A; Hayano, S; Inui, N; Iwashima, S; Kashiwagura, Y; Nagata, E; Nishida, M; Odagiri, K; Okada, E; Sano, S; Tanaka, S; Uchida, S; Umemura, K; Watanabe, H, 2022) |
| "Infantile hemangiomas are the most common benign vascular tumours in infants." | 1.72 | Evaluation of cases with infantile hemangioma requiring treatment. ( Acipayam, C; Dalgiç, EF; Dinçer, S; Güllü, UU; Karaküçük, SN; Maraşli, H; Yurttutan, S, 2022) |
| "Propranolol is a safe, effective and well-tolerated treatment in Australian children with IH." | 1.72 | Immediate possible adverse event rates in infants treated with oral propranolol for infantile haemangiomas at an Australian urban tertiary hospital between 2016 and 2019. ( Adams, L; Ryan, E, 2022) |
| "Severe hypoglycemia was common in infants aged >1 year, when PPL was used for ≥6 months." | 1.72 | Severe hypoglycemia in propranolol treatment for infantile hemangiomas. ( Baba, N; Kaneko, T; Kuwano, Y; Morimoto, A; Ozeki, M; Sasaki, S, 2022) |
| "Propranolol therapy was interrupted for several months while patient was maintained on a diuretic regimen and treated with vincristine and high-dose corticosteroids." | 1.72 | Mediastinal infantile hemangioma with spinal canal extension and extensive gastrointestinal involvement complicated by respiratory failure. ( Anselmo, DM; Cohen-Cutler, S; Detterich, JA; Luu, M; Mascarenhas, L; Miller, JM, 2022) |
| "Oral propranolol was effective in the treatment of pIH." | 1.72 | Comprehensive Management of Infantile Hemangiomas Involving the Periorbital Region. ( Chen, WL; Dong, XY; Hong, L; Lan, YQ, 2022) |
| " The propranolol starting dosage was 0." | 1.72 | Monitoring oral propranolol for infantile hemangiomata. ( Bar, J; Bar-Ilan, E; Cleper, R; Mashiah, J; Samuelov, L; Sprecher, E, 2022) |
| "Persistent cutaneous dysesthesias were present in seven patients, in most cases many years after completion of involution." | 1.62 | Persistent dysesthesias in involuted infantile hemangiomas: An uncommon complication in a common condition. ( Antaya, RJ; Braun, M; Frieden, IJ; Kohn, LL; Mancini, AJ; Metry, D, 2021) |
| "Mean propranolol treatment duration was 11." | 1.62 | Infantile Hemangiomas Cleared by Combined Therapy With Pulsed Dye Laser and Propranolol. ( Aoki, R; Ogawa, R; Sugimoto, A; Toyohara, E, 2021) |
| "Propranolol is an approved treatment for IHs, but its mechanism of action remains unclear." | 1.56 | Identification of putative biomarkers for Infantile Hemangiomas and Propranolol treatment via data integration. ( Dai, Y; Gomez-Acevedo, H; Richter, GT; Shawber, C; Strub, G; Wu, JK, 2020) |
| "Infantile hemangiomas are the most common benign vascular tumors in childhood." | 1.56 | Propranolol-resistant infantile hemangioma successfully treated with sirolimus. ( Baselga, E; Dávila-Osorio, VL; Iznardo, H; Puig, L; Roé, E, 2020) |
| "Propranolol was interrupted after complete or almost complete resolution of infantile haemangiomas." | 1.56 | Cutaneous Infantile Haemangiomas with Intracranial and Intraspinal Involvement: A European Multicentre Experience and Review. ( Carnevale, C; Diociaiuti, A; El Hachem, M; Figà-Talamanca, L; Léauté-Labrèze, C; Neri, I; Rotunno, R; Torres, EB, 2020) |
| "Propranolol is an effective, non-invasive treatment for life threatening infantile hemangiomas compressing the airway, should be used as a firstline treatment for subglottic hemangiomas when intervention is required." | 1.51 | A Life Threatening Subglottic and Mediastinal Hemangioma in an Infant. ( Gergin, O; Karabulut, B; Onder, SS, 2019) |
| "Propranolol has been the first-line treatment for alarming hemangiomas." | 1.48 | Intralesional Bleomycin Injection for Propranolol-Resistant Hemangiomas. ( Chang, L; Chen, H; Jin, Y; Lin, X; Ma, G; Yang, X, 2018) |
| " Atenolol and prednisolone are effective and safe alternatives to propranolol in the treatment of refractory IHs." | 1.48 | Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management. ( Chen, S; Ji, Y; Lu, G; Qiu, L; Wang, Q; Xiang, B; Xu, Z; Yang, K; Zhong, L, 2018) |
| "Propranolol treatment (2 mg/kg/day in three doses) for infantile haemangioma is well tolerated and safe and may be administered and monitored in an ambulatory setting." | 1.48 | Safety profile during initiation of propranolol for treatment of infantile haemangiomas in an ambulatory day-care hospitalization setting. ( Atar Snir, V; Ben-Amitai, D; Fogel, I; Friedland, R; Lapidoth, M; Ollech, A; Valdman-Greenshpon, Y; Zvulunov, A, 2018) |
| "Oral propranolol has become first-line intervention for problematic infantile hemangioma (IH) that is not amenable to topical or intralesional therapies." | 1.46 | Propranolol Treatment of Vascular Anomalies Other Than Infantile Hemangioma. ( Alomari, MH; Goss, JA; Greene, AK; Konczyk, DJ; Maclellan, RA, 2017) |
| "Propranolol is an effective drug in treating IH." | 1.46 | Ultrasonography as an objective tool for assessment of infantile hemangioma treatment with propranolol. ( Alvarenga, JG; Bouer, M; de Oliveira Labinas, GH; de Oliveira, ZN; Rivitti-Machado, MC; Rotter, A; Samorano, LP; Santos, PC; Silvestre, DA, 2017) |
| "Propranolol 4% gel is a safe and efficient topical therapy for IH." | 1.46 | Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas. ( Goldberg, I; Harel, A; Ilan, EB; Kutz, A; Mashiah, J; Rabia, SH; Sprecher, E, 2017) |
| "Propranolol is a safe and effective first-line therapy for problematic IHs." | 1.43 | Propranolol Therapy for Problematic Infantile Hemangioma. ( Knuth, C; Murthy, A; Ng, M; Weisbrod, C, 2016) |
| "Oral propranolol treatment caused a 47% reduction in mean induced astigmatism, less than the 63% reduction reported for the cohort treated with corticosteroid." | 1.43 | Visual acuity and astigmatism in periocular infantile hemangiomas treated with oral beta-blocker versus intralesional corticosteroid injection. ( Herlihy, EP; Kelly, JP; Perkins, JA; Sidbury, R; Weiss, AH, 2016) |
| "Propranolol is a well-tolerated, efficacious, and safe drug for treatment of IH." | 1.43 | Treatment with propranolol for infantile hemangiomas: single-center experience. ( Bör, Ö; Özdemir, ZC; Turhan, AB, 2016) |
| " The objective of this study was to investigate the effects of dosing protocol on the distribution of propranolol in the periocular tissues and plasma after topical ocular instillation." | 1.42 | Effects of dosing protocol on distribution of propranolol in periocular tissues after topical ocular instillation. ( Hao, J; Li, SK; Liu, H; Yang, MB, 2015) |
| "Propranolol was commenced at 0." | 1.42 | Low-dose propranolol regimen for infantile haemangioma. ( Itinteang, T; Leadbitter, P; Marsh, R; Tan, CE; Tan, ST, 2015) |
| "Oral propranolol hydrochloride has been proven effective in treating infantile hemangiomas, and its potential efficacy in choroidal hemangiomas has been suggested." | 1.42 | Effects of oral propranolol on a juxtapapillary capillary hemangioma: a single-subject pilot study. ( Hirose, H; Kitano, T; Sahashi, K; Saito, AM; Tanabe, H; Tomita, Y, 2015) |
| "Propranolol was initiated at 0." | 1.42 | Scoring the therapeutic effects of oral propranolol for infantile hemangioma: A prospective study comparing the Hemangioma Activity Score (HAS) with the Hemangioma Severity Scale (HSS). ( de Laat, PC; Janmohamed, SR; Madern, GC; Oranje, AP; van Oosterhout, M; van Rosmalen, J, 2015) |
| "Propranolol gel may suppress the proliferation of IHs by reducing VEGF." | 1.42 | Effect of topical propranolol gel on plasma renin, angiotensin II and vascular endothelial growth factor in superficial infantile hemangiomas. ( Chen, JW; Chen, SM; Chen, SQ; Li, CJ; Tang, YJ; Wang, L; Xia, Y; Yuan, B; Zhang, ZZ, 2015) |
| "Propranolol has been the first-line treatment for problematic infantile hemangioma (IH) since 2008." | 1.40 | Recurrence of infantile hemangioma after termination of propranolol treatment. ( Chang, L; Chen, H; Hu, X; Jin, Y; Lin, X; Ma, G; Qiu, Y; Yang, X; Ye, X; Yu, W, 2014) |
| "Propranolol (a β-blocker) is a safe treatment for problematic IH." | 1.40 | Propranolol in infantile haemangioma: simplifying pretreatment monitoring. ( de Buys Roessingh, A; El Ezzi, O; Hohlfeld, J, 2014) |
| "Propranolol has been reported to be used as a successful treatment of severe symptomatic infantile haemangiomas." | 1.40 | A complication to be aware of: hyperkalaemia following propranolol therapy for an infant with intestinal haemangiomatozis. ( Belen, B; Dalgic, B; Oguz, A; Okur, A, 2014) |
| "To evaluate the efficacy, adverse effects, and recurrence of oral propranolol for treatment of infantile hemangioma." | 1.39 | Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence. ( Li, Q; Xiao, Q; Yu, W; Zhang, B, 2013) |
| "Oral propranolol is now the treatment of choice in many situations." | 1.39 | Ulcerated nasal infantile haemangioma treated by oral propranolol. ( Al Dosari, S; Riad, H, 2013) |
| "Propranolol was stopped in 1 case for hypotension and in 1 case for allergy." | 1.39 | Treatment of infantile capillary hemangioma of the eyelid with systemic propranolol. ( Di Mezza, A; Forte, R; Magli, A; Vassallo, P, 2013) |
| "Propranolol has recently been introduced as a novel pharmacologic treatment for infantile haemangiomas, after Leaute-Labreze and colleagues observed that two patients being treated for cardiac indications had rapid regression of their haemangiomas." | 1.39 | Capillary haemangioma successfully treated with oral beta-blocker in Dar es Salaam, Tanzania: a case report. ( Blaikie, A; Cloke, A; Lim, LT, 2013) |
| "Oral propranolol was clinically effective in reducing the volume and color of infantile hemangiomas, although the reduction was not complete and telangiectasia and scarring persisted after treatment." | 1.38 | Outpatient treatment of infantile hemangiomas with propranolol: a prospective study. ( Betlloch-Mas, I; Lucas-Costa, A; Martin de Lara, AI; Martínez-Miravete, MT; Selva-Otalaurruchi, J, 2012) |
| "Oral propranolol was started in an ambulatory way at a dose of 2mg/kg daily divided in two doses." | 1.38 | Oral propranolol for treating infantile hemangiomas: a case series of 57 patients. ( Abarzúa-Araya, A; Navarrete-Dechent, C; Nicklas-Díaz, C; Silva-Valenzuela, S; Uribe-González, P; Zegpi-Trueba, MS, 2012) |
| "Propranolol seems to be an effective modality of treatment for periocular IH." | 1.37 | Treatment of periocular infantile hemangiomas with propranolol: case series of 18 children. ( Al Dhaybi, R; Chevrette, L; Codère, F; Dubois, J; Fallaha, N; Hamel, P; Hatami, A; McCuaig, C; Milet, A; Ospina, LH; Powell, J; Superstein, R, 2011) |
| "Oral propranolol for treatment of infantile hemangiomas was effective in all patients, with 33% reduction in astigmatism and 39% reduction in surface area." | 1.37 | Oral propranolol for treatment of periocular infantile hemangiomas. ( Bayliss, SJ; Gilbertson, K; Lueder, GT; Missoi, TG, 2011) |
| "Kaposiform hemangioendothelioma is a rare vascular tumor in children." | 1.37 | Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment. ( de Blaauw, I; Hermans, DJ; Kool, LJ; van Beynum, IM; van der Vijver, RJ; van der Vleuten, CJ, 2011) |
| " A treatment dosage of 2 mg/kg per day was started at mean age 5." | 1.37 | Refractive and structural changes in infantile periocular capillary haemangioma treated with propranolol. ( Ben-Amitay, D; Friling, R; Goldenberg-Cohen, N; Reich, U; Ron, Y; Siegel, R; Snir, M; Zvulunov, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (1.48) | 29.6817 |
| 2010's | 133 (65.52) | 24.3611 |
| 2020's | 67 (33.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yüksel, H | 1 |
| Yaşar, A | 1 |
| Gürbüz, N | 1 |
| Bizbirlik, ZI | 1 |
| Yilmaz, Ö | 1 |
| Ye, Y | 1 |
| Zhong, H | 1 |
| Dou, L | 1 |
| Song, W | 1 |
| Dong, C | 1 |
| Lu, W | 1 |
| Dong, K | 1 |
| Li, K | 1 |
| Li, J | 2 |
| He, L | 1 |
| Gao, W | 2 |
| Xia, C | 1 |
| Wang, L | 5 |
| Rikihisa, N | 1 |
| Takatsuka, H | 1 |
| Suzuki, T | 1 |
| Shiko, Y | 1 |
| Kawasaki, Y | 1 |
| Hanawa, M | 1 |
| Ishii, I | 1 |
| Mitsukawa, N | 1 |
| Pope, E | 2 |
| Lara-Corrales, I | 1 |
| Sibbald, C | 1 |
| Liy-Wong, C | 1 |
| Kanigsberg, N | 1 |
| Drolet, B | 1 |
| Ma, J | 1 |
| Meyer-Mueller, C | 1 |
| Nicholson, C | 1 |
| Polcari, I | 1 |
| Boull, C | 1 |
| Maguiness, S | 1 |
| Twist, J | 1 |
| Chen, A | 2 |
| Poffenberger, P | 1 |
| Zinn, Z | 1 |
| Gatts, JE | 1 |
| Rush, MC | 1 |
| Check, JF | 1 |
| Samelak, DM | 1 |
| McLean, TW | 1 |
| Chen, T | 1 |
| Gudipudi, R | 1 |
| Nguyen, SA | 1 |
| Carroll, W | 1 |
| Clemmens, C | 1 |
| Chang, SJ | 2 |
| Chang, HF | 1 |
| Qiu, Y | 4 |
| Chang, L | 5 |
| Jin, Y | 4 |
| Lin, X | 6 |
| Colmenero, M | 1 |
| Del Boz, J | 1 |
| Bernabeu Wittel, J | 1 |
| Roé, E | 2 |
| Feito-Rodríguez, M | 1 |
| Vicente-Villa, MA | 1 |
| Martín-Santiago, A | 1 |
| Palencia Pérez, SI | 1 |
| Azon, A | 1 |
| Valdivielso-Ramos, M | 1 |
| Torrelo, A | 2 |
| Sánchez Moya, AI | 1 |
| Campos-Domínguez, M | 1 |
| Garnacho-Saucedo, G | 1 |
| Azaña Defez, JM | 1 |
| Vera Casaño, Á | 1 |
| Tercedor-Sánchez, J | 1 |
| Alcalá, R | 1 |
| González-Enseyat, MA | 1 |
| Giacaman, A | 1 |
| Hernández-Martin, Á | 1 |
| Monserrat García, MT | 1 |
| Bauzá, A | 1 |
| Domínguez-Cruz, J | 1 |
| García-Doval, I | 1 |
| Grau-Pérez, M | 1 |
| Hermans, MM | 3 |
| Breugem, CC | 3 |
| Schappin, R | 3 |
| Jonge Poerink, E | 1 |
| Mendels, EJ | 3 |
| Ragamin, A | 1 |
| Breur, JMPJ | 3 |
| Langeveld, HR | 3 |
| Raphael, MF | 4 |
| De Laat, PCJ | 3 |
| De Wildt, SN | 3 |
| Rietman, AB | 3 |
| Pasmans, SGMA | 3 |
| De Graaf, M | 3 |
| Nagata, E | 1 |
| Kashiwagura, Y | 1 |
| Okada, E | 1 |
| Tanaka, S | 1 |
| Sano, S | 1 |
| Nishida, M | 1 |
| Hayano, S | 1 |
| Iwashima, S | 1 |
| Hakamata, A | 1 |
| Odagiri, K | 1 |
| Inui, N | 1 |
| Watanabe, H | 1 |
| Umemura, K | 1 |
| Uchida, S | 1 |
| Ishikawa, T | 1 |
| Seki, K | 1 |
| Uchiyama, H | 1 |
| Song, D | 1 |
| Guo, L | 1 |
| Ganeva, K | 1 |
| Shivachev, P | 1 |
| Sapundzhiev, N | 1 |
| Nikiforova, L | 1 |
| Maraşli, H | 1 |
| Acipayam, C | 1 |
| Güllü, UU | 1 |
| Dinçer, S | 1 |
| Dalgiç, EF | 1 |
| Karaküçük, SN | 1 |
| Yurttutan, S | 1 |
| Pensabene, M | 1 |
| Di Pace, MR | 1 |
| Baldanza, F | 1 |
| Grasso, F | 1 |
| Patti, M | 1 |
| Sergio, M | 1 |
| La Placa, S | 1 |
| Giuffre', M | 1 |
| Serra, G | 1 |
| Casuccio, A | 1 |
| Cimador, M | 1 |
| Adams, L | 1 |
| Ryan, E | 1 |
| Dong, J | 1 |
| Rong, H | 1 |
| Dong, Z | 1 |
| Wang, T | 3 |
| Liu, S | 1 |
| Morimoto, A | 2 |
| Ozeki, M | 2 |
| Sasaki, S | 3 |
| Baba, N | 2 |
| Kuwano, Y | 2 |
| Kaneko, T | 2 |
| Cohen-Cutler, S | 1 |
| Detterich, JA | 1 |
| Miller, JM | 1 |
| Anselmo, DM | 1 |
| Luu, M | 1 |
| Mascarenhas, L | 1 |
| Chen, WL | 2 |
| Lan, YQ | 1 |
| Hong, L | 1 |
| Dong, XY | 1 |
| Bar, J | 1 |
| Bar-Ilan, E | 2 |
| Cleper, R | 1 |
| Sprecher, E | 2 |
| Samuelov, L | 1 |
| Mashiah, J | 3 |
| Kleinman, EP | 1 |
| Blei, F | 2 |
| Adams, D | 2 |
| Greenberger, S | 1 |
| Hasbani, DJ | 1 |
| Hamie, L | 1 |
| Léauté-Labrèze, C | 8 |
| Frieden, I | 2 |
| Delarue, A | 2 |
| Chen, Q | 1 |
| Zhou, L | 1 |
| Yu, Z | 2 |
| Chen, J | 1 |
| Li, H | 2 |
| Fu, R | 1 |
| Zou, Y | 1 |
| Wu, Z | 1 |
| Jin, P | 1 |
| Cheng, J | 2 |
| Bai, H | 1 |
| Huang, M | 1 |
| Huan, X | 1 |
| Yuan, H | 1 |
| Höger, PH | 1 |
| Hamm, H | 1 |
| Gonzalez Martinez, OG | 1 |
| Langer, PD | 1 |
| Milman, T | 1 |
| Khamaysi, Z | 1 |
| Pam, N | 1 |
| Zaaroura, H | 1 |
| Avitan-Hersh, E | 1 |
| Mauguen, C | 1 |
| Maruani, A | 1 |
| Barbarot, S | 1 |
| Abasq, C | 1 |
| Martin, L | 1 |
| Herbert, J | 1 |
| Goronflot, T | 1 |
| Gourraud, PA | 1 |
| Happe, A | 1 |
| Descatha, A | 1 |
| Chrétien, JM | 1 |
| Beuchée, A | 1 |
| Adamski, H | 1 |
| Dupuy, A | 1 |
| Bouzillé, G | 1 |
| Oger, E | 1 |
| Droitcourt, C | 1 |
| Liu, C | 2 |
| Deng, L | 1 |
| Wang, Q | 2 |
| Huang, L | 1 |
| Gao, J | 1 |
| Chen, X | 1 |
| Chen, S | 6 |
| Volonté, M | 1 |
| Codazzi, AC | 1 |
| Davidovich, S | 1 |
| Apicella, A | 1 |
| Isoletta, E | 1 |
| Barruscotti, S | 1 |
| Massa, M | 1 |
| Silvestri, A | 1 |
| Marseglia, GL | 1 |
| Brazzelli, V | 1 |
| Ojha, HR | 1 |
| Verma, N | 1 |
| Alshammari, H | 1 |
| Alessa, A | 1 |
| Elsharawy, Y | 1 |
| Alghanem, A | 1 |
| Alhammad, AM | 1 |
| Al-Haddad, C | 1 |
| El Salloukh, NA | 1 |
| El Moussawi, Z | 1 |
| Janmohamed, SR | 5 |
| Harris, J | 1 |
| Phillips, JD | 1 |
| Howard, MA | 1 |
| Olitsky, SE | 1 |
| Rychwalski, P | 1 |
| Mungan, N | 1 |
| Mehta, A | 1 |
| Bajaj, MS | 1 |
| Pushker, N | 1 |
| Chawla, B | 1 |
| Pujari, A | 1 |
| Grewal, SS | 1 |
| Grewal, SPS | 1 |
| Singh, SR | 1 |
| Kishore, A | 1 |
| Yadav, NS | 1 |
| Tripathy, D | 1 |
| Chelleri, C | 1 |
| Monzani, NA | 1 |
| Gelmetti, C | 2 |
| Milani, GP | 1 |
| Fossali, EF | 1 |
| Galeone, C | 1 |
| Cavalli, R | 2 |
| Lin, Z | 1 |
| Zhang, B | 3 |
| Li, L | 2 |
| Yang, B | 1 |
| Wei, L | 1 |
| Han, XF | 1 |
| Xu, ZG | 1 |
| Ma, L | 1 |
| Gomez-Acevedo, H | 1 |
| Dai, Y | 1 |
| Strub, G | 1 |
| Shawber, C | 1 |
| Wu, JK | 2 |
| Richter, GT | 2 |
| Duell, K | 1 |
| McNab, S | 1 |
| Püttgen, KB | 1 |
| Hansen, LM | 1 |
| Lauren, C | 1 |
| Stefanko, N | 1 |
| Mathes, E | 1 |
| Olsen, GM | 1 |
| Tollefson, MM | 2 |
| Baselga, E | 4 |
| Chamlin, S | 1 |
| Corey, K | 1 |
| Frascari, FF | 1 |
| Frieden, IJ | 3 |
| Galligan, ER | 1 |
| Gupta, D | 1 |
| Haggstrom, A | 1 |
| Horii, K | 1 |
| Hornik, CP | 1 |
| Klajn, J | 1 |
| Liberman, L | 1 |
| Mancini, A | 1 |
| Mannschreck, D | 1 |
| McGinness, A | 1 |
| McCuaig, C | 3 |
| Newell, B | 1 |
| Nguyen, H | 1 |
| Nopper, A | 1 |
| Oyesanya, T | 1 |
| Powell, J | 2 |
| Reynolds, M | 1 |
| Rios, M | 1 |
| Siegel, DH | 1 |
| Ward, K | 1 |
| Garzon, MC | 2 |
| Frommelt, P | 1 |
| Drolet, BA | 1 |
| Dávila-Osorio, VL | 1 |
| Iznardo, H | 1 |
| Puig, L | 1 |
| Sazali, HB | 1 |
| Allen, NM | 1 |
| Murphy, A | 1 |
| Sun, LM | 1 |
| Xu, Y | 2 |
| Xu, MN | 2 |
| Wang, M | 2 |
| Su, Y | 1 |
| Yuan, SM | 2 |
| Ishikawa, K | 1 |
| Fujita, M | 1 |
| Takeda, T | 1 |
| Mitamura, S | 1 |
| Nishio, T | 1 |
| Funayama, E | 1 |
| Hayashi, T | 1 |
| Osawa, M | 1 |
| Maeda, T | 1 |
| Yamamoto, Y | 1 |
| Koren, A | 1 |
| Friedman, O | 1 |
| Zur, E | 1 |
| Artzi, O | 1 |
| Yang, H | 2 |
| Hu, DL | 2 |
| Xuan, XX | 1 |
| Chen, JJ | 1 |
| Xu, S | 2 |
| Wu, XJ | 1 |
| Zhang, H | 2 |
| Shu, Q | 2 |
| Guo, XD | 2 |
| Bonafede, L | 1 |
| Go, M | 1 |
| Belcastro, AA | 1 |
| Bellet, JS | 2 |
| Gabr, H | 1 |
| Freedman, SF | 1 |
| Velez, FG | 1 |
| Diociaiuti, A | 1 |
| Carnevale, C | 1 |
| Torres, EB | 1 |
| Neri, I | 1 |
| Rotunno, R | 1 |
| Figà-Talamanca, L | 1 |
| El Hachem, M | 1 |
| Liang, Y | 1 |
| Pu, R | 1 |
| Huang, X | 1 |
| Li, S | 2 |
| Chen, Y | 1 |
| Tang, W | 1 |
| Galdeano, F | 1 |
| Herón, A | 1 |
| Moreno, S | 1 |
| Aprea, G | 1 |
| Meneses, M | 1 |
| Saerens, J | 2 |
| Gutermuth, J | 1 |
| De Leye, H | 1 |
| Moisan, F | 2 |
| Oucherif, S | 1 |
| Kaulanjan-Checkmodine, P | 1 |
| Prey, S | 2 |
| Rousseau, B | 1 |
| Bonneu, M | 1 |
| Claverol, S | 1 |
| Gontier, E | 1 |
| Lacomme, S | 1 |
| Dousset, L | 1 |
| Couffinhal, T | 1 |
| Toutain, J | 1 |
| Loot, M | 2 |
| Cario-André, M | 2 |
| Jullié, ML | 1 |
| Taieb, A | 4 |
| Rezvani, HR | 1 |
| Lee, JC | 1 |
| Modiri, O | 1 |
| England, RW | 1 |
| Shawber, CJ | 1 |
| Ji, Y | 4 |
| Yang, K | 4 |
| Zhang, X | 2 |
| Zhou, J | 2 |
| Xiang, B | 3 |
| Qiu, T | 2 |
| Dai, S | 3 |
| Jiang, X | 2 |
| Lu, G | 3 |
| Qiu, L | 2 |
| Kong, F | 2 |
| Zhang, Y | 2 |
| Xu, X | 1 |
| Qiu, Q | 1 |
| Miyazaki, T | 1 |
| Sasai, H | 1 |
| Ohnishi, H | 1 |
| Börjesson, C | 1 |
| Malloizel-Delaunay, J | 1 |
| Onnis, G | 2 |
| Mazereeuw-Hautier, J | 2 |
| Dreyfus, I | 2 |
| Braun, M | 1 |
| Metry, D | 1 |
| Antaya, RJ | 1 |
| Mancini, AJ | 1 |
| Kohn, LL | 1 |
| Sugimoto, A | 1 |
| Aoki, R | 1 |
| Toyohara, E | 1 |
| Ogawa, R | 1 |
| Sebaratnam, DF | 1 |
| Rodríguez Bandera, AL | 1 |
| Wong, LF | 1 |
| Wargon, O | 3 |
| Dornhoffer, JR | 1 |
| Wei, T | 1 |
| Miller, E | 1 |
| A Cleves, M | 1 |
| Feng, H | 1 |
| Kauvar, ANB | 1 |
| Kurta, AO | 1 |
| Dai, D | 1 |
| Armbrecht, ES | 1 |
| Siegfried, EC | 3 |
| Koh, K | 1 |
| Matsui, K | 1 |
| Ohjimi, H | 1 |
| Hayashi, N | 1 |
| Nakano, A | 1 |
| Ohki, K | 1 |
| Tamaki, Z | 1 |
| Kakazu, M | 1 |
| Kishi, K | 1 |
| Oyama, T | 1 |
| Sato, A | 1 |
| Kato, R | 1 |
| Higuchi, T | 1 |
| Moyakine, AV | 3 |
| Herwegen, B | 1 |
| van der Vleuten, CJM | 2 |
| Goss, JA | 1 |
| Konczyk, DJ | 1 |
| Alomari, MH | 1 |
| Maclellan, RA | 1 |
| Greene, AK | 1 |
| Marey, HM | 1 |
| Elmazar, HF | 1 |
| Mandour, SS | 1 |
| Khairy, HA | 1 |
| Ginguerra, MA | 1 |
| Saito, O | 1 |
| Fernandes, JBVD | 1 |
| Castro, DS | 1 |
| Matayoshi, S | 1 |
| Koka, K | 1 |
| Mukherjee, B | 1 |
| Agarkar, S | 1 |
| Chen, H | 3 |
| Yang, X | 3 |
| Ma, G | 3 |
| Seamens, A | 1 |
| Nieman, E | 1 |
| Losavio, K | 1 |
| Bradley, B | 1 |
| Nelson, K | 1 |
| Chen, KH | 1 |
| Arbiser, J | 1 |
| Lawley, LP | 1 |
| Karimi, S | 1 |
| Nikkhah, H | 1 |
| Ahmadieh, H | 1 |
| Safi, S | 1 |
| Xu, Z | 1 |
| Zhong, L | 1 |
| Fogel, I | 1 |
| Ollech, A | 1 |
| Zvulunov, A | 2 |
| Valdman-Greenshpon, Y | 1 |
| Atar Snir, V | 1 |
| Friedland, R | 1 |
| Lapidoth, M | 1 |
| Ben-Amitai, D | 1 |
| Lameiro, TMDM | 1 |
| Denadai, R | 1 |
| Pereira-Filho, JC | 1 |
| Raposo-Amaral, CA | 1 |
| Raposo-Amaral, CE | 1 |
| Ford, JR | 1 |
| Gonzalez-Barlatay, J | 1 |
| Valenzuela, AA | 1 |
| Novoa, M | 1 |
| Beltran, S | 1 |
| Giraldo, L | 1 |
| Shahbaz, A | 1 |
| Pardo-Hernandez, H | 1 |
| Arevalo-Rodriguez, I | 1 |
| Frongia, G | 1 |
| Byeon, JO | 1 |
| Arnold, R | 1 |
| Mehrabi, A | 1 |
| Günther, P | 1 |
| Itesako, T | 1 |
| Eura, R | 1 |
| Okamoto, Y | 1 |
| Tatarano, S | 1 |
| Yoshino, H | 1 |
| Nishimura, H | 1 |
| Yamada, Y | 1 |
| Enokida, H | 1 |
| Nakagawa, M | 1 |
| Albanese, G | 1 |
| Mohandas, P | 1 |
| Wells, L | 1 |
| Ravenscroft, J | 1 |
| Srinivasan, J | 1 |
| Thomas, S | 2 |
| Taylor, T | 1 |
| Tambe, K | 1 |
| Zhang, M | 1 |
| Hutchinson, AK | 1 |
| Kraker, RT | 1 |
| Pineles, SL | 1 |
| VanderVeen, DK | 1 |
| Wilson, LB | 1 |
| Galvin, JA | 1 |
| Lambert, SR | 1 |
| Ganti, AK | 1 |
| Ray, J | 1 |
| Mooney, KL | 1 |
| Zambrano, E | 1 |
| Hillard, PJA | 1 |
| Fok, W | 1 |
| O'Brien, KF | 1 |
| Shah, SD | 1 |
| Phillips, RJ | 2 |
| Haggstrom, AN | 1 |
| Hoeger, PH | 1 |
| Treat, JR | 1 |
| Perman, MJ | 1 |
| Cubiró, X | 1 |
| Poole, J | 1 |
| Babic, V | 1 |
| Schoeffler, A | 1 |
| Moawad, S | 1 |
| Mainard, L | 1 |
| Schmutz, JL | 1 |
| Bursztejn, AC | 1 |
| Krick, J | 1 |
| Riehle, K | 1 |
| Chapman, T | 1 |
| Chabra, S | 1 |
| Peng, S | 1 |
| Chen, L | 1 |
| Dakoutrou, M | 1 |
| Alexopoulos, A | 1 |
| Miligkos, M | 1 |
| Georgiadou, E | 1 |
| Kanaka-Gantenbein, C | 1 |
| Kakourou, T | 1 |
| Miraglia, E | 1 |
| Schiavetti, A | 1 |
| Varrasso, G | 1 |
| Celli, M | 1 |
| Calvieri, S | 1 |
| Giustini, S | 1 |
| Gumina, ME | 1 |
| Yan, AC | 2 |
| Ho, W | 1 |
| Hoo, C | 1 |
| Black, C | 1 |
| van Schaijik, B | 1 |
| Tan, ST | 3 |
| Marsh, RW | 1 |
| Itinteang, T | 3 |
| Putterman, E | 1 |
| Wan, J | 1 |
| Streicher, JL | 1 |
| Onder, SS | 1 |
| Gergin, O | 1 |
| Karabulut, B | 1 |
| Dalby, TK | 1 |
| Lester-Smith, D | 1 |
| Lee, KC | 1 |
| Bercovitch, L | 1 |
| Xiao, Q | 1 |
| Li, Q | 1 |
| Yu, W | 3 |
| Zhai, YN | 1 |
| Song, HT | 1 |
| Chen, SQ | 2 |
| Zhang, MX | 1 |
| Li, CJ | 2 |
| Xia, Y | 2 |
| Gunturi, N | 1 |
| Ramgopal, S | 1 |
| Balagopal, S | 1 |
| Scott, JX | 1 |
| Yen, KG | 1 |
| Hussein, MA | 1 |
| Ozyörük, D | 1 |
| Zengin, E | 1 |
| Al Dosari, S | 1 |
| Riad, H | 1 |
| Herschthal, J | 1 |
| Wulkan, A | 1 |
| George, M | 1 |
| Waibel, J | 1 |
| Theunissen, CI | 1 |
| Smitt, JH | 1 |
| van der Horst, CM | 1 |
| Broeks, IJ | 1 |
| Hermans, DJ | 3 |
| Dassel, AC | 1 |
| van der Vleuten, CJ | 4 |
| van Beynum, IM | 2 |
| May, JE | 1 |
| Liew, SH | 1 |
| Patel, NJ | 1 |
| Bauman, NM | 1 |
| Lacour, JP | 1 |
| Ye, X | 2 |
| Hu, X | 1 |
| Albuquerque, JC | 1 |
| Magalhães, RA | 1 |
| Félix, JA | 1 |
| Bastos, MV | 1 |
| Fontenele, JB | 1 |
| Trompieri, NM | 1 |
| Felix, FH | 1 |
| El Ezzi, O | 1 |
| Hohlfeld, J | 1 |
| de Buys Roessingh, A | 1 |
| Gonski, K | 1 |
| Ábarzúa-Araya, A | 2 |
| Navarrete-Dechent, CP | 1 |
| Heusser, F | 1 |
| Retamal, J | 1 |
| Zegpi-Trueba, MS | 2 |
| Pain, C | 1 |
| Vergnes, P | 1 |
| Heaton, P | 1 |
| Kennedy, C | 1 |
| Amin, S | 1 |
| Jia, R | 1 |
| Ge, S | 1 |
| Lin, M | 1 |
| Fan, X | 1 |
| Belen, B | 1 |
| Oguz, A | 1 |
| Okur, A | 1 |
| Dalgic, B | 1 |
| Lokmic, Z | 2 |
| Crock, CM | 1 |
| Penington, A | 2 |
| Bellaud, G | 1 |
| Puzenat, E | 1 |
| Billon-Grand, NC | 1 |
| Humbert, P | 1 |
| Aubin, F | 1 |
| Handgretinger, R | 1 |
| Natawidjaja, R | 2 |
| Wang, E | 1 |
| Madern, GC | 2 |
| de Laat, PC | 2 |
| Oranje, AP | 2 |
| Liu, H | 1 |
| Yang, MB | 1 |
| Li, SK | 1 |
| Hao, J | 1 |
| Tan, CE | 1 |
| Leadbitter, P | 2 |
| Marsh, R | 2 |
| Oksiuta, M | 1 |
| Matuszczak, E | 1 |
| Dębek, W | 1 |
| Dzienis-Koronkiewicz, E | 1 |
| Hermanowicz, A | 1 |
| Tylicka, M | 1 |
| Ovadia, SA | 1 |
| Landy, DC | 1 |
| Cohen, ER | 1 |
| Yang, EY | 1 |
| Thaller, SR | 1 |
| Ewen Wang, N | 1 |
| Tanabe, H | 1 |
| Sahashi, K | 1 |
| Kitano, T | 1 |
| Tomita, Y | 1 |
| Saito, AM | 1 |
| Hirose, H | 1 |
| Ng, M | 1 |
| Knuth, C | 1 |
| Weisbrod, C | 1 |
| Murthy, A | 1 |
| Jacks, SK | 1 |
| Kertesz, NJ | 1 |
| Witman, PM | 1 |
| Fernandez Faith, E | 1 |
| Lv, D | 1 |
| van Oosterhout, M | 1 |
| van Rosmalen, J | 1 |
| Fuijkschot, J | 1 |
| Rouhana, HF | 1 |
| Fruge, JH | 1 |
| Massengale, WT | 1 |
| Tang, YJ | 1 |
| Zhang, ZZ | 1 |
| Chen, SM | 1 |
| Chen, JW | 1 |
| Yuan, B | 1 |
| Tang, LY | 1 |
| Hing, JW | 1 |
| Tang, JY | 1 |
| Nishikawa, H | 1 |
| Shahidullah, H | 1 |
| Browne, F | 1 |
| Chikermane, A | 1 |
| Parulekar, M | 1 |
| Sulzberger, L | 1 |
| Baillie, R | 1 |
| de Jong, S | 1 |
| Cavalheiro, S | 1 |
| Campos, HG | 1 |
| Silva da Costa, MD | 1 |
| Seidmann, L | 1 |
| Anspach, L | 1 |
| Roth, W | 1 |
| Herlihy, EP | 1 |
| Kelly, JP | 1 |
| Sidbury, R | 1 |
| Perkins, JA | 1 |
| Weiss, AH | 1 |
| Salamat, AA | 1 |
| Casselden, E | 1 |
| Theaker, J | 1 |
| Batty, V | 1 |
| Kerstjens, JM | 1 |
| Spillekom-van Koulil, S | 1 |
| Taylor, RH | 1 |
| Turhan, AB | 1 |
| Bör, Ö | 1 |
| Özdemir, ZC | 1 |
| Fernando, SJ | 1 |
| Leitenberger, S | 1 |
| Majerus, M | 1 |
| Krol, A | 1 |
| MacArthur, CJ | 2 |
| Rizvi, SA | 1 |
| Mehmood, F | 1 |
| Agrawal, A | 1 |
| Ren, W | 1 |
| Gao, L | 1 |
| Huang, S | 1 |
| Zhang, L | 1 |
| Qiang, C | 1 |
| Zhi, K | 1 |
| Yarbrough, KB | 1 |
| Krol, AL | 1 |
| Leitenberger, SL | 1 |
| Mann, JA | 1 |
| Rotter, A | 1 |
| Samorano, LP | 1 |
| de Oliveira Labinas, GH | 1 |
| Alvarenga, JG | 1 |
| Rivitti-Machado, MC | 1 |
| Bouer, M | 1 |
| Santos, PC | 1 |
| Silvestre, DA | 1 |
| de Oliveira, ZN | 1 |
| Kutz, A | 1 |
| Rabia, SH | 1 |
| Ilan, EB | 1 |
| Goldberg, I | 1 |
| Harel, A | 1 |
| Smithson, SL | 1 |
| Rademaker, M | 1 |
| Adams, S | 1 |
| Bade, S | 1 |
| Bekhor, P | 1 |
| Davidson, S | 1 |
| Dore, A | 1 |
| Drummond, C | 1 |
| Fischer, G | 1 |
| Gin, A | 1 |
| Grills, C | 1 |
| Halbert, A | 1 |
| McCahon, E | 1 |
| Morgan, VA | 1 |
| Murrell, DF | 1 |
| Orchard, D | 1 |
| Purvis, D | 1 |
| Relic, J | 1 |
| Robertson, S | 1 |
| Robinson, AJ | 1 |
| Scardamaglia, L | 1 |
| Su, J | 1 |
| Tan, S | 1 |
| Warren, L | 1 |
| Wong, LC | 1 |
| Zappala, T | 1 |
| Phillips, R | 1 |
| Dumas de la Roque, E | 1 |
| Hubiche, T | 1 |
| Boralevi, F | 1 |
| Thambo, JB | 1 |
| Keenan, WJ | 1 |
| Al-Jureidini, S | 1 |
| Marsciani, A | 1 |
| Pericoli, R | 1 |
| Alaggio, R | 1 |
| Brisigotti, M | 1 |
| Vergine, G | 1 |
| Manunza, F | 1 |
| Syed, S | 1 |
| Laguda, B | 1 |
| Linward, J | 1 |
| Kennedy, H | 1 |
| Gholam, K | 1 |
| Glover, M | 1 |
| Giardini, A | 1 |
| Harper, JI | 1 |
| Taban, M | 1 |
| Goldberg, RA | 1 |
| Fulkerson, DH | 1 |
| Agim, NG | 1 |
| Al-Shamy, G | 1 |
| Metry, DW | 1 |
| Izaddoost, SA | 1 |
| Jea, A | 1 |
| Cruz, OA | 1 |
| Sloan, B | 1 |
| Mora, J | 1 |
| Fabian, ID | 1 |
| Ben-Zion, I | 1 |
| Samuel, C | 1 |
| Spierer, A | 1 |
| Claerhout, I | 1 |
| Buijsrogge, M | 1 |
| Delbeke, P | 1 |
| Walraedt, S | 1 |
| De Schepper, S | 1 |
| De Moerloose, B | 1 |
| De Groote, K | 1 |
| Decock, C | 1 |
| Mai, C | 1 |
| Vega-Pérez, A | 1 |
| Koch, M | 1 |
| Bertelmann, E | 1 |
| Al Dhaybi, R | 1 |
| Superstein, R | 1 |
| Milet, A | 1 |
| Dubois, J | 1 |
| Codère, F | 1 |
| Hatami, A | 1 |
| Chevrette, L | 1 |
| Fallaha, N | 1 |
| Hamel, P | 1 |
| Ospina, LH | 1 |
| Wester, ST | 1 |
| Johnson, TE | 1 |
| Missoi, TG | 1 |
| Lueder, GT | 1 |
| Gilbertson, K | 1 |
| Bayliss, SJ | 1 |
| Spierer, O | 1 |
| Neudorfer, M | 1 |
| Leibovitch, I | 1 |
| Stolovitch, C | 1 |
| Kessler, A | 1 |
| van der Vijver, RJ | 1 |
| Kool, LJ | 1 |
| de Blaauw, I | 1 |
| Sciveres, M | 1 |
| Marrone, G | 1 |
| Pipitone, S | 1 |
| Riva, S | 1 |
| Spada, M | 1 |
| Gridelli, B | 1 |
| Maggiore, G | 1 |
| Koay, AC | 1 |
| Choo, MM | 1 |
| Nathan, AM | 1 |
| Omar, A | 1 |
| Lim, CT | 1 |
| Chai, Q | 1 |
| Huang, ZQ | 1 |
| Zhang, DM | 1 |
| Fan, S | 1 |
| Thoumazet, F | 1 |
| Colin, J | 1 |
| Mortemousque, B | 1 |
| Ni, N | 1 |
| Guo, S | 1 |
| Langer, P | 1 |
| Spiteri Cornish, K | 1 |
| Reddy, AR | 1 |
| Snir, M | 1 |
| Reich, U | 1 |
| Siegel, R | 1 |
| Friling, R | 1 |
| Goldenberg-Cohen, N | 1 |
| Ron, Y | 1 |
| Ben-Amitay, D | 1 |
| Williams, K | 1 |
| Woolf, R | 1 |
| Morrison, D | 1 |
| Aletaha, M | 1 |
| Salour, H | 1 |
| Bagheri, A | 1 |
| Raffati, N | 1 |
| Amouhashemi, N | 1 |
| Clifford, L | 1 |
| May, K | 1 |
| Buffon, RB | 1 |
| de Souza, M | 1 |
| Colli, AM | 1 |
| Betlloch-Mas, I | 1 |
| Martínez-Miravete, MT | 1 |
| Lucas-Costa, A | 1 |
| Martin de Lara, AI | 1 |
| Selva-Otalaurruchi, J | 1 |
| Hadaschik, E | 1 |
| Scheiba, N | 1 |
| Engstner, M | 1 |
| Flux, K | 1 |
| Norris, JH | 1 |
| McCulloch, PG | 1 |
| Hirahara, S | 1 |
| Matsuda, K | 1 |
| Toyama, K | 1 |
| Nagano, Y | 1 |
| Nagai, N | 1 |
| Tono, T | 1 |
| Silva-Valenzuela, S | 1 |
| Navarrete-Dechent, C | 1 |
| Uribe-González, P | 1 |
| Nicklas-Díaz, C | 1 |
| Vassallo, P | 1 |
| Forte, R | 1 |
| Di Mezza, A | 1 |
| Magli, A | 1 |
| Xue, K | 1 |
| Hildebrand, GD | 1 |
| Vlastarakos, PV | 1 |
| Papacharalampous, GX | 1 |
| Chrysostomou, M | 1 |
| Tavoulari, EF | 1 |
| Delidis, A | 1 |
| Protopapas, D | 1 |
| Nikolopoulos, TP | 1 |
| Salazar-Murillo, R | 1 |
| García-Pacheco, S | 1 |
| González-Blanco, MJ | 1 |
| Bolívar-Montesa, P | 1 |
| Campos-García, S | 1 |
| Cloke, A | 1 |
| Lim, LT | 1 |
| Blaikie, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nadolol Versus Propranolol in Children With Infantile Hemangiomas: a Randomized, Controlled, Double-blinded Trial[NCT02505971] | Phase 3 | 74 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma[NCT02342275] | Phase 3 | 377 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Propranolol vs Prednisolone for Infant Hemangiomas-A Clinical and Molecular Study[NCT00967226] | Phase 2 | 19 participants (Actual) | Interventional | 2009-07-31 | Terminated (stopped due to Serious adverse events with prednisolone, primarily temporary growth retardation, <5th percentile.) | ||
| Propanolol Effect on Red Cell Adhesion in Non-Asthmatic Children With Sickle Cell Disease: A Dose Finding Study[NCT02012777] | Phase 1 | 9 participants (Actual) | Interventional | 2010-06-30 | Terminated (stopped due to Inability to recruit patients into the study.) | ||
| A Randomised, Controlled, Multidose, Multicentre, Adaptive Phase II/III Study in Infants With Proliferating Infantile Hemangiomas (IHs) Requiring Systemic Therapy to Compare 4 Regimens of Propranolol (1 or 3 mg/kg/Day for 3 or 6 Months) to Placebo (Double[NCT01056341] | Phase 2/Phase 3 | 512 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Melablock: A Multicentre Randomized, Double---blinded and Placebo---controlled Clinical Trial on the Efficacy and Safety of Once Daily Propranolol 80 mg Retard for the Prevention of Cutaneous Malignant Melanoma Recurrence[NCT02962947] | Phase 2/Phase 3 | 546 participants (Anticipated) | Interventional | 2017-06-30 | Not yet recruiting | ||
| "'' Efficacy of Propranolol in the Treatment of Infantile Hemangioma"[NCT04684667] | Phase 2 | 100 participants (Anticipated) | Interventional | 2021-01-01 | Not yet recruiting | ||
| Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations[NCT02335242] | Phase 2 | 22 participants (Actual) | Interventional | 2015-05-23 | Completed | ||
| A Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Proliferative and Involuting Cutaneous Infantile Hemangioma[NCT01072045] | Phase 2 | 50 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Modular Open Label, Signal Seeking, Phase II Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (TARGET-VM)[NCT05983159] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-09-30 | Not yet recruiting | ||
| Double Blind, Randomised, Placebo-controlled Study of Propranolol in Infantile Capillary Hemangiomas[NCT00744185] | Phase 2/Phase 3 | 14 participants (Actual) | Interventional | 2008-10-31 | Terminated (stopped due to Study halted prematurely due to some difficulties in recruitment of patients) | ||
| Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol[NCT01533376] | Phase 1 | 3 participants (Actual) | Interventional | 2012-02-29 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The complete healing time of the ulceration was defined as the time from the first dosage of propranolol or atenolol until complete healing of the hemangioma ulceration (assessed up to 6 months). Ulceration is defined as a break in the integrity of the hemangioma surface epithelium (or skin) with or without infection. The information included the extent of ulceration, complications of ulceration, prior duration of ulceration (before treatment), concurrent treatments, and complete healing time. Prior duration of ulceration was defined as the time from the first sign of ulceration until before β-blocker treatment. The complete healing time of the ulceration was defined as the time from the first dosage of propranolol or atenolol until complete healing of the hemangioma ulceration. Concurrent treatments, including oral pain medication, oral antibiotics, topical ointment antibiotics and/or wound dressings, were permitted to treat ulcerated IH and were recorded. (NCT02342275)
Timeframe: from the first dosage of propranolol or atenolol until complete healing ofthe hemangioma ulceration.
| Intervention | weeks (Mean) |
|---|---|
| Propranolol | 4.94 |
| Atenolol | 4.82 |
A complete/nearly complete response at week 96 was considered median-term efficacy. (NCT02342275)
Timeframe: 96 week
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 156 |
| Atenolol | 149 |
Regrowth of more than 20% in hemangioma appearance (including changes in color and/or volume) after stopping the medication was considered significant rebound. The inclusion criteria for rebound analysis were as follows: (1) patients who completed 6 months of treatment and (2) patients who discontinued therapy or were tapering treatment after achieving an any response. The exclusion criteria were as follows: (1) patients who were noncompliant with treatment and (2) patients who did not respond to treatment. Whether a patient had hemangioma rebound was based on the site investigators' assessments after the week 24 treatment. In patients with significant rebound, reinitiation of systemic therapy (either propranolol or atenolol) was recommended. Minor rebound, which was defined as those patients in whose rebound was noted but no reinitiation of systemic therapy or further treatment was necessary, was not included in the analysis. (NCT02342275)
Timeframe: between weeks 24 and 96
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 19 |
| Atenolol | 12 |
"A successful initial response was defined as a HAS score decrease at 1 week after treatment.~A successful initial response was assessed by using HAS in the intention-to-treat population. Previous studies demonstrated that HAS decreases over time after β-blocker treatment, with a dramatic drop occurring in the first week, indicating an immediate therapeutic response. HAS can reflect the rapid effect of β-blocker (either propranolol or atenolol) therapy shortly after initiation." (NCT02342275)
Timeframe: 1 week after treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 171 |
| Atenolol | 163 |
"Changes in IH size and color were classified as a complete response, nearly complete response, partial response or no response. The primary outcome measure was any response at 6 months in the intention-to-treat population of all patients who underwent randomization. The any response included compete, nearly complete and partial responses.~A complete response was defined as no redundant tissue or telangiectasia was identified.~A nearly complete response was defined as a minimal degree of telangiectasis, erythema and skin thickening.~A partial response was defined as a size reduction or change in color that did not meet the nearly complete resolution criteria." (NCT02342275)
Timeframe: 6 month
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 178 |
| Atenolol | 173 |
"HAS was measured at baseline and at 1, 4, 12, and 24 weeks, including the degree of deep swelling, the color of the hemangioma, and the ulceration assessment:~Assessment of the degree of swelling. It was scored as follows:~6 points if the swelling was tense;~4 points if the swelling was'neutral;~2 points when the swelling was reduced by 50% or more at follow-up; or~0 point when there was no more visible swelling at a follow-up.~Assessment of the color of the IH.~5 points if the hemangioma lesion was bright red all over;~3 points if the hemangioma lesion was matte red or reddish-purple;~1 point if the hemangioma lesion was totally or partially gray;~0 points if the hemangioma lesion was totally or partially skin-colored after involution.~(2) Assessment of the ulceration. -0.5 point for an ulcer ≤1.0 cm2;~One point for an ulcer >1.0 cm2 but <25 cm2;~Two points for an ulcer ≥25 cm2. The HAS score= (Swelling score + color score)/2 +Ulceration score." (NCT02342275)
Timeframe: Baseline and at 1, 4, 12, and 24 weeks
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 1 | Week 4 | Week 12 | Week 24 | |
| Atenolol | 4.54 | 3.47 | 2.33 | 1.54 | 0.82 |
| Propranolol | 4.61 | 3.31 | 2.42 | 1.54 | 0.82 |
Number of allergy/immunology AE per study arm (NCT00967226)
Timeframe: enrollment through study closeout or study withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Allergy/Immunology Events Propranolol | 1 |
| Allergy/Immunology Events Prednisolone | 1 |
Number of constitutional AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study close out or withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Constitutional AEs Propranolol | 2 |
| Constitutional AEs Prednisolone | 3 |
A priori primary outcome was proportional change in the total surface area as measured by lesion's outer margin length x width at baseline minus the same measure at 4 months with surrogate data used at 5 months if 4 months not available. (NCT00967226)
Timeframe: 4-5 months after initiating therapy
| Intervention | mm squared (Mean) |
|---|---|
| Propranolol | 0.57 |
| Prednisolone | 0.63 |
Number of Dermatologic Adverse Events in each study arm. (NCT00967226)
Timeframe: enrollment to study close out or withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Dermatologic AEs Propranolol | 2 |
| Dermatologic AEs Prednisolone | 1 |
Number of Endocrinologic AEs (of which adrenal crisis does not overlap). (NCT00967226)
Timeframe: enrollment to close out or study withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Endocrine AEs Propranolol | 0 |
| Endocrinologic AEs Prednisolone | 7 |
Number of Gastrointestinal AEs in each arm (NCT00967226)
Timeframe: enrollment to study withdrawal or study close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Gastrointestinal AEs Propranolol | 6 |
| Gastrointestinal AEs Prednisolone | 6 |
Number of Growth and Development AEs in each study arm (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Growth/Developoment AEs Propranolol | 0 |
| Growth/Development AEs Prednisolone | 1 |
Number of infectious AEs in each study arm (i.e. conjunctivitis, thrush, fever) (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Infectious AEs Propranolol | 5 |
| Infectious AEs Prednisolone | 3 |
Number of Metabolic or Laboratory AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Metabolic/Laboratory AEs Propranolol | 1 |
| Metabolic/Laboratory AEs Prednisolone | 0 |
Number of serious adverse events experienced by the participants in each treatment arm within the categories adrenal crisis, growth/development, constitutional. Serious adverse events are defined as events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity, or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered Serious Adverse Events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned. (NCT00967226)
Timeframe: enrollment until study close out or withdrawal up to 9 months
| Intervention | Serious Adverse Events (Number) |
|---|---|
| Number of Serious Adverse Events in Propranolol | 1 |
| Number of Serious Adverse Events in Prednisolone | 11 |
Number of pulmonary/respiratory adverse events (CTCAE 22) in each study arm (NCT00967226)
Timeframe: enrollment through study close out or withdrawal, up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Pulmonary/Respiratory AEs Propranolol | 14 |
| Pulmonary/Respiratory AEs Prednisolone | 4 |
Number of Vascular AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Vascular AEs Propranolol | 3 |
| Vascular AEs Prednisolone | 4 |
All adverse events relating to medication tolerability including: adrenal crisis, growth/development, constitutional (dehydration), allergy/immunology, dermatologic, endocrine, GI, infection, metabolism/labs, pulmonary, vascular. (NCT00967226)
Timeframe: enrollment until study close out or withdrawal up to 9 months
| Intervention | Events (Number) | |
|---|---|---|
| Adverse Events | Serious Adverse Events | |
| Overall Number of Adverse Events in Prednisolone | 30 | 11 |
| Overall Number of Adverse Events in Propranolol | 34 | 1 |
(NCT01056341)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 8.0 |
| Propranolol 1mg/kg/d 3 Months | 9.8 |
| Propranolol 1 mg/kg/d 6 Months | 37.5 |
| Propranolol 3 mg/kg/d 3 Months | 7.7 |
| Propranolol 3 mg/kg/d 6 Months | 62.8 |
(NCT01056341)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 3.6 |
| Propranolol 3mg/kg/d 6 Months | 60.4 |
Participants will be followed for the duration of the study, an expected average of 20 weeks. (NCT02335242)
Timeframe: Baseline, week 20
| Intervention | percentage of volume (Mean) |
|---|---|
| Double-Blind Placebo | 5.89 |
| Open-Label Sildenafil | -8.54 |
| Double-blind Sildenafil | -0.642 |
"Subject's evaluation of the overall change in lymphatic malformation. Participants will be followed from baseline to 20 weeks.~Patients rated change as no improvement, minimal improvement (1-25% change), fair improvement (25-50% change), good improvement (50-75% change), and excellent improvement (75-100% change)." (NCT02335242)
Timeframe: Baseline, week 20
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| No improvement | Minimal improvement | Fair improvement | Good improvement | Excellent improvement | |
| Double-Blind Placebo | 1 | 2 | 0 | 2 | 0 |
| Double-Blind Sildenafil | 2 | 4 | 1 | 1 | 0 |
38 reviews available for propranolol and Hemangioma, Capillary
| Article | Year |
|---|---|
Should Propranolol Remain the Gold Standard for Treatment of Infantile Hemangioma? A Systematic Review and Meta-Analysis of Propranolol Versus Atenolol.
Topics: Adrenergic beta-Antagonists; Atenolol; Drug-Related Side Effects and Adverse Reactions; Hemangioma; | 2023 |
Propranolol treatment of infantile subglottic hemangioma: a report of two cases and a literature review.
Topics: Child; Hemangioma; Hemangioma, Capillary; Humans; Infant; Laryngeal Neoplasms; Laryngoscopy; Propran | 2021 |
Sirolimus for diffuse intestinal infantile hemangioma with PHACE features: systematic review.
Topics: Aortic Coarctation; Eye Abnormalities; Female; Hemangioma; Hemangioma, Capillary; Humans; Infant; Pr | 2023 |
Infantile Hemangiomas.
Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outcome | 2022 |
[Infantile hemangioma : Clinical manifestation, treatment, and differential diagnoses].
Topics: Child; Diagnosis, Differential; Hemangioma; Hemangioma, Capillary; Humans; Neoplasms, Vascular Tissu | 2023 |
β-blockers in the treatment of periocular infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Infant; Ma | 2019 |
Residual Lesions After Pharmacological and Dye-Laser Treatment of Infantile Hemangiomas: Critical Review of 432 Cases.
Topics: Hemangioma, Capillary; Humans; Infant; Lasers, Dye; Observational Studies as Topic; Propranolol; Ski | 2020 |
The effectiveness and safety of topical β-receptor blocker in treating superficial infantile haemangiomas: A meta-analysis including 20 studies.
Topics: Administration, Topical; Adrenergic beta-Antagonists; China; Drug-Related Side Effects and Adverse R | 2020 |
The efficacy and safety of treatments for infantile hemangiomas: a Bayesian network meta-analysis.
Topics: Bayes Theorem; Hemangioma, Capillary; Humans; Network Meta-Analysis; Propranolol; Timolol | 2020 |
News on infantile haemangioma. Part 2: therapy and evaluation.
Topics: Adrenergic beta-Antagonists; Cost of Illness; Hemangioma, Capillary; Humans; Infant; Laser Therapy; | 2021 |
Propranolol Therapy in Infantile Hemangioma: It Is Not Just About the Beta.
Topics: Adrenergic beta-Antagonists; Hemangioma, Capillary; Humans; Infant; Propranolol | 2021 |
Infantile hemangioma. Part 2: Management.
Topics: Adrenergic beta-Antagonists; COVID-19; Hemangioma, Capillary; Humans; Infant; Nevus; Pandemics; Prop | 2021 |
Interventions for infantile haemangiomas of the skin.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Antineoplastic Agents; Bleomycin; Child, Presc | 2018 |
Orbital infantile haemangioma: radiological features and treatment - case series and literature review.
Topics: Female; Hemangioma, Capillary; Humans; Infant; Infant, Newborn; Magnetic Resonance Imaging; Male; Or | 2019 |
The Use of β-Blockers for the Treatment of Periocular Hemangiomas in Infants: A Report by the American Academy of Ophthalmology.
Topics: Academies and Institutes; Adrenergic beta-Antagonists; Child, Preschool; Eyelid Neoplasms; Hemangiom | 2019 |
[Rare presentations of infantile hemangiomas: 4 cases].
Topics: Biopsy; Buttocks; Delayed Diagnosis; Erythema; Facial Neoplasms; Female; Foot Diseases; Hemangioma, | 2018 |
Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies.
Topics: Administration, Oral; Child; Hemangioma, Capillary; Humans; Propranolol; Treatment Outcome | 2019 |
Propranolol for the treatment of infantile haemangioma.
Topics: Hemangioma, Capillary; Humans; Infant; Nose Neoplasms; Propranolol; Randomized Controlled Trials as | 2013 |
Update on infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Infant; Infant, Newborn; Male; N | 2013 |
Propranolol therapy for infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Hemangioma, Capillary; Humans; Infant; Propranolol; Treatment Outcome | 2013 |
Propranolol versus corticosteroids: what should be the treatment of choice in infantile hemangiomas?
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Child, Preschool; Cohort Studies; Female; Hemangioma | 2015 |
Propranolol treatment in life-threatening airway hemangiomas: a case series and review of literature.
Topics: Administration, Oral; Airway Obstruction; Biopsy, Needle; Critical Illness; Dose-Response Relationsh | 2013 |
How should propranolol be initiated for infantile hemangiomas: inpatient versus outpatient?
Topics: Administration, Oral; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based | 2014 |
[What’s new in pediatric dermatology?].
Topics: Adolescent; Child; Dermatitis, Atopic; Dermatology; Hemangioma, Capillary; Humans; Melanoma; Neoplas | 2013 |
Treatment of periorbital infantile haemangiomas: a systematic literature review on propranolol or steroids.
Topics: Adrenal Cortex Hormones; Hemangioma, Capillary; Humans; Infant; Orbital Neoplasms; Propranolol; Vaso | 2014 |
Treatment of complex infantile haemangioma in a resource-poor setting.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Female; Follow- | 2014 |
Educational paper: Pathogenesis of infantile haemangioma, an update 2014 (part I).
Topics: Adrenergic beta-Antagonists; Hemangioma, Capillary; Humans; Hypoxia-Inducible Factor 1, alpha Subuni | 2015 |
Treatment of problematic infantile hemangiomas with propranolol: a series of 40 cases and review of the literature.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Infant; In | 2014 |
Local administration of β-blockers for infantile hemangiomas: a systematic review and meta-analysis.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Hemangioma, Capillary; Humans; Infant; Injec | 2015 |
Beta blocker treatment for infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Atenolol; Child; Child, Preschool; Dose-Response | 2015 |
A case of giant fetal intracranial capillary hemangioma cured with propranolol.
Topics: Adrenergic beta-Antagonists; Brain Neoplasms; Female; Fetal Diseases; Hemangioma, Capillary; Humans; | 2016 |
Middle ear capillary haemangioma: Review of literature and appraisal of management options.
Topics: Adrenergic beta-Antagonists; Child; Ear Neoplasms; Ear, Middle; Hemangioma, Capillary; Humans; Magne | 2016 |
[Efficacy of beta-blockers in infantile capillary haemangiomas: the physiopathological significance and therapeutic consequences].
Topics: Adrenergic beta-Antagonists; Age Factors; Apoptosis; Child; Child, Preschool; Female; Hemangioma, Ca | 2008 |
Emergent medical and surgical management of mediastinal infantile hemangioma with symptomatic spinal cord compression: case report and literature review.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Anticoagulants; Child, Preschool; Decompressi | 2010 |
The use of propranolol in the treatment of periocular infantile haemangiomas: a review.
Topics: Adrenergic beta-Antagonists; Disease Progression; Eye Neoplasms; Hemangioma, Capillary; Humans; Infa | 2011 |
Current concepts in the management of periocular infantile (capillary) hemangioma.
Topics: Administration, Oral; Administration, Topical; Adrenergic beta-Antagonists; Child, Preschool; Eyelid | 2011 |
The use of propranolol in the management of periocular capillary haemangioma--a systematic review.
Topics: Administration, Oral; Antineoplastic Agents; Child, Preschool; Disease Progression; Evidence-Based M | 2011 |
Propranolol is an effective treatment for airway haemangiomas: a critical analysis and meta-analysis of published interventional studies.
Topics: Hemangioma, Capillary; Humans; Infant; Propranolol; Respiratory Tract Neoplasms; Treatment Outcome | 2012 |
9 trials available for propranolol and Hemangioma, Capillary
| Article | Year |
|---|---|
Efficacy and Safety of Propranolol Gel for Infantile Hemangioma: A Randomized, Double-Blind Study.
Topics: Adrenergic beta-Antagonists; Child; Double-Blind Method; Gels; Hemangioma, Capillary; Humans; Infant | 2022 |
Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Double-Blind Method; Equivalence Trials as Topic; | 2022 |
Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2023 |
Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2023 |
Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2023 |
Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2023 |
To compare intralesional and oral propranolol for treating periorbital and eyelid capillary hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Eyelid Neoplasms; Female; Hemangioma, Capillary; | 2019 |
Efficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Atenolol; China; Female; Hemang | 2021 |
Efficacy and safety of oral propranolol for infantile hemangioma in Japan.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Administration Schedule; Female; Follow-Up S | 2017 |
Combined Oral and Topical Beta Blockers for the Treatment of Early Proliferative Superficial Periocular Infantile Capillary Hemangioma.
Topics: Administration, Oral; Administration, Topical; Adrenergic beta-Antagonists; Drug Therapy, Combinatio | 2018 |
Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study.
Topics: Adrenergic beta-Antagonists; Atenolol; Dose-Response Relationship, Drug; Drug Administration Schedul | 2014 |
Is Propranolol Safe and Effective for Outpatient Use for Infantile Hemangioma? A Prospective Study of 679 Cases From One Center in China.
Topics: Adrenergic beta-Antagonists; Ambulatory Care; China; Female; Follow-Up Studies; Hemangioma, Capillar | 2016 |
156 other studies available for propranolol and Hemangioma, Capillary
| Article | Year |
|---|---|
Infantile Glottic Hemangioma: Bronchoscopic Evaluation and Propranolol Treatment.
Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Treatment Outcome | 2021 |
Propranolol inhibits the angiogenic capacity of hemangioma endothelia via blocking β-adrenoceptor in mast cell.
Topics: Cell Proliferation; Cytokines; Endothelial Cells; Hemangioma; Hemangioma, Capillary; Humans; Mast Ce | 2022 |
Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2022 |
Propranolol therapy for hemangiomas in infants with neonatal abstinence syndrome may produce intolerable side effects.
Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Iatrogenic Disease; Infant; | 2022 |
Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma; Hemangioma, | 2022 |
Does Oral Propranolol Improve the Final Outcome of All Involuted Infantile Hemangiomas? A Matched Retrospective Comparative Study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Disease Progression; Hemangioma; Hemangioma, Capi | 2022 |
Inter- and intra-observer variability in the selection of therapy for infantile hemangiomas among pediatric dermatologists in Spain.
Topics: Child; Cross-Sectional Studies; Dermatologists; Hemangioma; Hemangioma, Capillary; Humans; Observer | 2022 |
Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma.
Topics: Adrenergic beta-Antagonists; Atenolol; Cross-Sectional Studies; Esthetics; Hemangioma; Hemangioma, C | 2022 |
Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2022 |
Efficacy of intravenous propranolol for life-threatening diffuse neonatal hemangiomatosis.
Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Infant, Newborn; Liver Neoplasms; Propranolol; Tr | 2022 |
Clinical evaluation of transcatheter arterial embolization combined with propranolol orally treatment of infantile hepatic hemangioma.
Topics: Child; Embolization, Therapeutic; Female; Heart Failure; Hemangioma; Hemangioma, Capillary; Humans; | 2022 |
Evaluation of cases with infantile hemangioma requiring treatment.
Topics: Administration, Oral; Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Skin Neoplasms | 2022 |
Quality of life improving after propranolol treatment in patients with Infantile Hemangiomas.
Topics: Administration, Oral; Drug-Related Side Effects and Adverse Reactions; Hemangioma, Capillary; Humans | 2022 |
Immediate possible adverse event rates in infants treated with oral propranolol for infantile haemangiomas at an Australian urban tertiary hospital between 2016 and 2019.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Australia; Hemangioma; Hemangioma, Capillary; Hos | 2022 |
Influence of systemic propranolol treatment on the physical development of pediatric patients with infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Hemangioma, Capillary; Humans; Infant; Pro | 2023 |
Severe hypoglycemia in propranolol treatment for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Child; Female; Hemangioma; Hemangioma, Capillary; Humans; Hypoglycemia; | 2022 |
Mediastinal infantile hemangioma with spinal canal extension and extensive gastrointestinal involvement complicated by respiratory failure.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Diuretics; Hemangioma; Hemangioma, Capillary; | 2022 |
Comprehensive Management of Infantile Hemangiomas Involving the Periorbital Region.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Face; Hemangioma, Capillary; Humans; Infant; Prop | 2022 |
Monitoring oral propranolol for infantile hemangiomata.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Bradycardia; Child; Hemangioma, Capillary; Humans | 2022 |
Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Atenolol; Child; Cross-Sectional Studies; Female; Hemangioma; Hemangiom | 2023 |
Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Atenolol; Child; Cross-Sectional Studies; Female; Hemangioma; Hemangiom | 2023 |
Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Atenolol; Child; Cross-Sectional Studies; Female; Hemangioma; Hemangiom | 2023 |
Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Atenolol; Child; Cross-Sectional Studies; Female; Hemangioma; Hemangiom | 2023 |
Distribution of problematic localized facial infantile haemangiomas and their response to propranolol: a retrospective cohort study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2023 |
Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2023 |
Propranolol-induced Involution of Infantile Hemangioma.
Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Skin Ne | 2023 |
Nd:YAG 1064-nm laser for residual infantile hemangioma after propranolol treatment.
Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Lasers, Solid-State; Propranolol; Prospective Stu | 2023 |
Factors associated with early relapse of infantile haemangioma in children treated for at least six months with oral propranolol: A case-control study using the 2014-2021 French Ouest DataHub.
Topics: Administration, Oral; Case-Control Studies; Child; Chronic Disease; Hemangioma, Capillary; Humans; I | 2023 |
The impact of propranolol on the growth and development of children with proliferative infantile hemangioma during treatment.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Growth and Development; Hemangioma; Hemang | 2023 |
Propranolol for the treatment of infantile hemangiomas: a nine-year monocentric experience from a tertiary hospital.
Topics: Hemangioma, Capillary; Humans; Infant; Infant, Newborn; Propranolol; Tertiary Care Centers; Vascular | 2023 |
Early management of capillary haemangioma to prevent stimulus-deprivation amblyopia.
Topics: Amblyopia; Child; Eyelid Neoplasms; Female; Hemangioma, Capillary; Humans; Infant; Propranolol; Timo | 2022 |
Excessively High Chronic Propranolol Overdose in Infantile Hemangioma: A Case Report.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Drug Overdose; Female; Hemangioma; Hemangi | 2023 |
Comment on "Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas".
Topics: Hemangioma; Hemangioma, Capillary; Humans; Propranolol; Timolol | 2019 |
Evaluating the Clinical Outcomes of Parotid Hemangiomas in the Pediatric Patient Population.
Topics: Adrenal Cortex Hormones; Drug Administration Schedule; Female; Hemangioma; Hemangioma, Capillary; Hu | 2021 |
Management of Periocular Infantile Hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Eyelid Neoplasms; Female; Glucocorticoids; Hemang | 2019 |
Commentary: Propranolol for infantile hemangiomas - The intralesional route.
Topics: Eyelid Neoplasms; Hemangioma; Hemangioma, Capillary; Humans; Propranolol | 2019 |
Application of the adenosine triphosphate sensitivity assay in infantile vascular anomalies.
Topics: Adenosine Triphosphate; Hemangioma, Capillary; Humans; Infant; Propranolol; Vascular Malformations | 2020 |
Identification of putative biomarkers for Infantile Hemangiomas and Propranolol treatment via data integration.
Topics: Adaptor Proteins, Signal Transducing; Aldehyde Dehydrogenase 1 Family; Antiporters; Apoptosis; Basic | 2020 |
Propranolol and topical timolol for infantile haemangiomas of the skin.
Topics: Hemangioma; Hemangioma, Capillary; Humans; Propranolol; Skin; Timolol | 2020 |
Limited utility of repeated vital sign monitoring during initiation of oral propranolol for complicated infantile hemangioma.
Topics: Administration, Oral; Female; Hemangioma, Capillary; Humans; Infant; Infant, Newborn; Male; Monitori | 2021 |
Propranolol-resistant infantile hemangioma successfully treated with sirolimus.
Topics: Adrenergic beta-Antagonists; Child; Hemangioma; Hemangioma, Capillary; Humans; Infant; Prednisolone; | 2020 |
PHACE syndrome: importance of distinguishing infantile haemangioma from capillary malformation.
Topics: Adrenergic beta-Antagonists; Aortic Coarctation; Diagnosis, Differential; Eye Abnormalities; Female; | 2020 |
Diagnosis and treatment of periorbital infantile hemangiomas: Case series and literature review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Female; Follow-Up Studi | 2020 |
Ulcerated Infantile Hemangioma of the Hard Palate: Diagnostic Treatment With Oral Propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Infant; Pa | 2020 |
Enhanced Percutaneous Delivery of Beta-Blockers Using Thermal Resurfacing Drug Delivery System for Topical Treatment of Infantile Hemangiomas.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Drug Delivery Systems; Female; Hemangioma, Cap | 2020 |
Periocular infantile hemangioma masquerading as dacryocele.
Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Lacrimal Duct Obstruction; Male; Nasolacrimal Duc | 2020 |
Cutaneous Infantile Haemangiomas with Intracranial and Intraspinal Involvement: A European Multicentre Experience and Review.
Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Retrosp | 2020 |
Airway obstruction as the primary manifestation of infantile thyroid hemangioma.
Topics: Adrenergic beta-Antagonists; Airway Obstruction; Diagnosis, Differential; Diagnostic Imaging; Female | 2020 |
Multiple pulmonary infantile hemangiomas responsive to oral propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2021 |
An infant with localized vasoconstriction following topical propranolol exposure for infantile hemangioma.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Hemangioma, Capillary; Humans; Infant; Propran | 2021 |
Critical role of Aquaporin-1 and telocytes in infantile hemangioma response to propranolol beta blockade.
Topics: Adrenergic beta-Antagonists; Animals; Aquaporin 1; Cell Line, Tumor; Cell Movement; Hemangioma, Capi | 2021 |
Propranolol for the treatment of ulcerated infantile hemangiomas: A prospective study.
Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Prospec | 2022 |
Propranolol for infantile hemangiomas with hyperinsulinemic hypoglycemia.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Hypogl | 2021 |
Value of Doppler ultrasound scans in deciding whether to treat infantile haemangioma with oral propranolol.
Topics: Adrenergic beta-Antagonists; Child; Hemangioma, Capillary; Humans; Infant; Propranolol; Retrospectiv | 2021 |
Persistent dysesthesias in involuted infantile hemangiomas: An uncommon complication in a common condition.
Topics: Administration, Cutaneous; Adolescent; Adult; Child; Child, Preschool; Hemangioma; Hemangioma, Capil | 2021 |
Infantile Hemangiomas Cleared by Combined Therapy With Pulsed Dye Laser and Propranolol.
Topics: Administration, Oral; Cicatrix; Cohort Studies; Combined Modality Therapy; Dose-Response Relationshi | 2021 |
The expression of renin-angiotensin-aldosterone axis components in infantile hemangioma tissue and the impact of propranolol treatment.
Topics: Angiotensinogen; Cell Proliferation; Child, Preschool; Female; Hemangioma, Capillary; Humans; Infant | 2017 |
Successful Treatment of a Residual, Thick, Infantile Hemangioma in a Darker Phototype Pediatric Patient Using the 755-nm Long-Pulsed Alexandrite Laser.
Topics: Cardiovascular Agents; Child, Preschool; Female; Hemangioma, Capillary; Humans; Lasers, Gas; Lasers, | 2017 |
Prescribing propranolol for infantile hemangioma: Assessment of dosing errors.
Topics: Health Care Surveys; Hemangioma, Capillary; Humans; Infant; Medication Errors; Propranolol; Skin Neo | 2017 |
Use of the Hemangioma Severity Scale to facilitate treatment decisions for infantile hemangiomas.
Topics: Clinical Decision-Making; Cohort Studies; Databases, Factual; Female; Follow-Up Studies; Hemangioma; | 2017 |
Propranolol Treatment of Vascular Anomalies Other Than Infantile Hemangioma.
Topics: Adrenergic beta-Antagonists; Adult; Child; Child, Preschool; Diagnostic Errors; Female; Hemangioma, | 2017 |
Clinical and Radiological Evaluation of Periocular Infantile Hemangioma Treated With Oral Propranolol: A Case Series.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Dose-Response Relationship, Dru | 2018 |
Effect of oral propranolol on periocular Capillary Hemangiomas of Infancy.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Infant; Ma | 2018 |
Intralesional Bleomycin Injection for Propranolol-Resistant Hemangiomas.
Topics: Antibiotics, Antineoplastic; Bleomycin; Drug Resistance, Neoplasm; Hemangioma, Capillary; Humans; In | 2018 |
Factors associated with delayed referral for infantile hemangioma necessitating propranolol.
Topics: Age of Onset; Clinical Competence; Female; Health Knowledge, Attitudes, Practice; Hemangioma, Capill | 2018 |
Salivary levels of angiopoietin-2 in infants with infantile haemangiomas treated with and without systemic propranolol.
Topics: Angiopoietin-2; Female; Hemangioma, Capillary; Humans; Infant; Male; Neoplastic Syndromes, Hereditar | 2018 |
INTRAVITREAL INJECTION OF PROPRANOLOL FOR THE TREATMENT OF RETINAL CAPILLARY HEMANGIOMA IN A CASE OF VON HIPPEL-LINDAU.
Topics: Adrenergic beta-Antagonists; Adult; Electroretinography; Fluorescein Angiography; Hemangioma, Capill | 2020 |
Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management.
Topics: Adrenergic beta-Antagonists; Drug-Related Side Effects and Adverse Reactions; Female; Hemangioma, Ca | 2018 |
Safety profile during initiation of propranolol for treatment of infantile haemangiomas in an ambulatory day-care hospitalization setting.
Topics: Ambulatory Care; Analysis of Variance; Child, Preschool; Cohort Studies; Dose-Response Relationship, | 2018 |
Treatment of Facial Infantile Hemangioma: Comparative Study Between Propranolol and Ethanolamine Oleate.
Topics: Face; Facial Neoplasms; Hemangioma, Capillary; Humans; Infant; Oleic Acids; Propranolol; Retrospecti | 2018 |
Early orbital infantile hemangioma that emphasizes the importance of glucose-transporter-1 (GLUT-1).
Topics: Administration, Oral; Adrenergic beta-Antagonists; Biomarkers, Tumor; Eye Neoplasms; Female; Glucose | 2018 |
Cardiac diagnostics before oral propranolol therapy in infantile hemangioma: retrospective evaluation of 234 infants.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Cardiac Imaging Techniques; Cohort Studies; Echoc | 2018 |
Oral Propranolol in a Child With Infantile Hemangioma of the Urethra.
Topics: Adrenergic beta-Antagonists; Child, Preschool; Cystoscopy; Hemangioma, Capillary; Hemorrhage; Humans | 2018 |
Individualized Treatment for Infantile Hemangioma.
Topics: Administration, Cutaneous; Administration, Oral; Betamethasone; Carteolol; Female; Glucocorticoids; | 2018 |
Unusual Cause of Pediatric Vaginal Bleeding: Infantile Capillary Hemangioma of the Cervix.
Topics: Adrenergic beta-Antagonists; Cervix Uteri; Child; Diagnosis, Differential; Endoscopy; Female; Hemang | 2019 |
Late growth of infantile hemangiomas in children >3 years of age: A retrospective study.
Topics: Adrenal Cortex Hormones; Age Factors; Child; Child, Preschool; Cohort Studies; Disease Progression; | 2019 |
Recurrent bloody stools associated with visceral infantile haemangioma in a preterm twin girl.
Topics: Adrenergic beta-Antagonists; Diagnosis, Differential; Female; Gastrointestinal Hemorrhage; Hemangiom | 2018 |
Efficacy of propranolol treatment in infantile hepatic haemangioma.
Topics: Hemangioma, Capillary; Humans; Infant; Outcome Assessment, Health Care; Propranolol; Retrospective S | 2019 |
Atenolol treatment for severe infantile hemangiomas: comparison with a propranolol group of our centre.
Topics: Atenolol; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; | 2019 |
Effectiveness of oral propranolol in a patient with neurofibromatosis type 1 and infantile hemangiomas.
Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Neurofibromatosis 1; Propranolol | 2021 |
Atenolol as an alternative to propranolol for the management of sleep disturbances in the treatment of infantile hemangiomas.
Topics: Administration, Oral; Atenolol; Drug Substitution; Female; Hemangioma, Capillary; Humans; Infant; Pa | 2019 |
Treatment of Infantile Haemangioma - Perspective of a Regional Surgical Centre.
Topics: Child; Child, Preschool; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Heman | 2019 |
Expression of (pro)renin receptor and its effect on endothelial cell proliferation in infantile hemangioma.
Topics: Antigens, CD34; Cell Differentiation; Cell Line; Cell Proliferation; Endothelial Cells; Female; Gene | 2019 |
Evaluation of a modified outpatient model for using propranolol to treat infantile hemangiomas.
Topics: Ambulatory Care; Blood Glucose; Blood Pressure Determination; Databases, Factual; Dose-Response Rela | 2019 |
[Infantile haemangioma; refer and treat on time].
Topics: Adrenergic beta-Antagonists; Directive Counseling; Early Diagnosis; Hemangioma, Capillary; Humans; I | 2019 |
A Life Threatening Subglottic and Mediastinal Hemangioma in an Infant.
Topics: Female; Hemangioma; Hemangioma, Capillary; Humans; Infant; Laryngeal Neoplasms; Mediastinal Neoplasm | 2019 |
Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma, Capillary; | 2013 |
[Effect of propranolol gel on infantile hemangiomas].
Topics: Female; Hemangioma, Capillary; Humans; Hydrogels; Infant; Infant, Newborn; Male; Propranolol; Skin N | 2013 |
Oral propranolol in the management of periocular capillary hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Eyelid Neoplasms; Hemangioma, Capillary; Humans; | 2013 |
Propranolol treatment of complicated hemangiomas.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Infant; Infant, Newborn; Male; P | 2014 |
Ulcerated nasal infantile haemangioma treated by oral propranolol.
Topics: Administration, Oral; Drug Administration Schedule; Female; Hemangioma, Capillary; Humans; Infant; N | 2013 |
Additive effect of propranolol and pulsed dye laser for infantile hemangioma.
Topics: Combined Modality Therapy; Female; Hemangioma, Capillary; Humans; Infant; Infant, Premature; Infant, | 2013 |
A new treatment pathway for propranolol use in infantile haemangiomas.
Topics: Hemangioma, Capillary; Humans; Infant; Infant, Newborn; Neoplastic Syndromes, Hereditary; Parents; P | 2014 |
Recurrence of infantile hemangioma after termination of propranolol treatment.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Infant; Neoplasm Recurrence, Loc | 2014 |
Treatment of children and adolescents with hemangioma using propranolol: preliminary results from a retrospective study.
Topics: Adolescent; Adrenergic beta-Antagonists; Age Factors; Chi-Square Distribution; Child; Child, Prescho | 2014 |
Propranolol in infantile haemangioma: simplifying pretreatment monitoring.
Topics: Blood Glucose; Blood Pressure; Drug Monitoring; Echocardiography; Electrocardiography; Facial Neopla | 2014 |
Retrospective follow up of gross motor development in children using propranolol for treatment of infantile haemangioma at Sydney Children's Hospital.
Topics: Adrenergic beta-Antagonists; Child Development; Follow-Up Studies; Hemangioma, Capillary; Hospitals, | 2014 |
Mast cells as possible targets of propranolol therapy: an immunohistological study of beta-adrenergic receptors in infantile haemangiomas.
Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Hemangioma, Capillary; Humans; Immunohistochem | 2014 |
Severe infantile haemangioma: complications and treatment.
Topics: Adrenergic beta-Antagonists; Hemangioma, Capillary; Humans; Infant; Propranolol; Skin Neoplasms | 2014 |
A complication to be aware of: hyperkalaemia following propranolol therapy for an infant with intestinal haemangiomatozis.
Topics: Albuterol; Angiography; Biopsy, Needle; Drug Therapy, Combination; Fluid Therapy; Follow-Up Studies; | 2014 |
Infantile haemangiomas that failed treatment with propranolol: clinical and histopathological features.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Biomarkers; Female; Hemangioma, Capillary; Humans | 2014 |
PHACE syndrome, a series of six patients: clinical and morphological manifestations, propranolol efficacy, and safety.
Topics: Aortic Coarctation; Child; Child, Preschool; Eye Abnormalities; Facial Neoplasms; Female; Hemangioma | 2015 |
How an accidental discovery paved the way for the treatment of complicated infantile haemangiomas.
Topics: Adrenergic beta-Antagonists; Facial Neoplasms; Hemangioma, Capillary; Humans; Male; Propranolol | 2014 |
Effects of dosing protocol on distribution of propranolol in periocular tissues after topical ocular instillation.
Topics: Adrenergic beta-Antagonists; Animals; Chromatography, Liquid; Dose-Response Relationship, Drug; Eye | 2015 |
Low-dose propranolol regimen for infantile haemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Drug Administra | 2015 |
Nonsurgical treatment of two cases of infantile facial growths in a resource-poor setting.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Indonesia; | 2015 |
Effects of oral propranolol on a juxtapapillary capillary hemangioma: a single-subject pilot study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Coloring Agents; Electroretinography; Female; Flu | 2015 |
Propranolol Therapy for Problematic Infantile Hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Ambulatory Care; Drug Administration Schedule; Fe | 2016 |
Experience with Holter monitoring during propranolol therapy for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Age Factors; Ambulatory Care; Cardiovascular Diseases; Child, Preschool | 2015 |
Scoring the therapeutic effects of oral propranolol for infantile hemangioma: A prospective study comparing the Hemangioma Activity Score (HAS) with the Hemangioma Severity Scale (HSS).
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Cohort Studies; Dose-Response R | 2015 |
Propranolol treatment of infantile hemangiomas does not negatively affect psychomotor development.
Topics: Child, Preschool; Cohort Studies; Female; Hemangioma, Capillary; Humans; Infant; Male; Neoplastic Sy | 2015 |
Effect of topical propranolol gel on plasma renin, angiotensin II and vascular endothelial growth factor in superficial infantile hemangiomas.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Angiotensin II; Case-Control Studies; Female | 2015 |
Predicting complications with pretreatment testing in infantile haemangioma treated with oral propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Dose-Response Relationship, Dru | 2016 |
Serum levels of renin, angiotensin-converting enzyme and angiotensin II in patients treated by surgical excision, propranolol and captopril for problematic proliferating infantile haemangioma.
Topics: Angiotensin II; Captopril; Cohort Studies; Female; Follow-Up Studies; Hemangioma, Capillary; Humans; | 2016 |
The embryo-placental CD15-positive "vasculogenic zones" as a source of propranolol-sensitive pediatric vascular tumors.
Topics: Age of Onset; Cell Lineage; Child; Drug Resistance, Neoplasm; Embryo, Mammalian; Endothelial Cells; | 2016 |
Visual acuity and astigmatism in periocular infantile hemangiomas treated with oral beta-blocker versus intralesional corticosteroid injection.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Astigmatism; Eyelid Neoplasms; Female; Glucocorti | 2016 |
Propranolol treatment of infantile hemangioma (IH) is not associated with developmental risk or growth impairment at age 4 years.
Topics: Body Height; Body Weight; Case-Control Studies; Child Development; Child, Preschool; Female; Hemangi | 2016 |
Infantile Periocular Haemangioma: Optimising the Therapeutic Response.
Topics: Adrenergic beta-Antagonists; Hemangioma, Capillary; Humans; Infant; Propranolol | 2016 |
Treatment with propranolol for infantile hemangiomas: single-center experience.
Topics: Child; Child, Preschool; Female; Hemangioma, Capillary; Humans; Infant; Male; Neoplastic Syndromes, | 2016 |
Use of intravenous propranolol for control of a large cervicofacial hemangioma in a critically ill neonate.
Topics: Airway Obstruction; Critical Illness; Enterocolitis, Necrotizing; Female; Hemangioma, Capillary; Hum | 2016 |
Bilateral congenital infantile hemangioma of upper eyelids.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Eyelid Neoplasms; Eyelids; Female; Hemangioma, Ca | 2016 |
Low-dose propranolol for infantile hemangioma of the head and neck: Analysis of 23 consecutive patients.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Child, Preschool; Dose-Response Relationsh | 2017 |
Patient Perspectives: Propranolol for infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Caregivers; Clinical Decision-Making; Female; Hem | 2016 |
Is Routine Electrocardiography Necessary Before Initiation of Propranolol for Treatment of Infantile Hemangiomas?
Topics: Adrenergic beta-Antagonists; Electrocardiography; Hemangioma; Hemangioma, Capillary; Humans; Infant; | 2016 |
Ultrasonography as an objective tool for assessment of infantile hemangioma treatment with propranolol.
Topics: Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma, Capillary; Humans; Infant; Male; | 2017 |
Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Age Factors; Child, Preschool; Female; Gels; | 2017 |
Consensus statement for the treatment of infantile haemangiomas with propranolol.
Topics: Consensus; Drug Monitoring; Hemangioma, Capillary; Humans; Neoplastic Syndromes, Hereditary; Patient | 2017 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
Propranolol for severe hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom | 2008 |
More on propranolol for hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Hemangioma, Capillary; Humans; Infant; Propranolol | 2008 |
More on propranolol for hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Hemangioma, Capillary; Humans; Infant; Propranolol | 2008 |
More on propranolol for hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Hemangioma, Capillary; Humans; Infant; Propranolol | 2008 |
More on propranolol for hemangiomas of infancy.
Topics: Adrenergic beta-Antagonists; Hemangioma, Capillary; Humans; Infant; Propranolol | 2008 |
Massive response of severe infantile hepatic hemangioma to propanolol.
Topics: Antineoplastic Agents, Phytogenic; Female; Hemangioma, Capillary; Humans; Infant; Liver Neoplasms; P | 2010 |
Propranolol for complicated infantile haemangiomas: a case series of 30 infants.
Topics: Adrenergic beta-Antagonists; Eyelid Neoplasms; Facial Neoplasms; Female; Follow-Up Studies; Glottis; | 2010 |
Propranolol for orbital hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Infant; Magnetic Resonance Imagi | 2010 |
Propranolol treatment for periocular capillary hemangiomas.
Topics: Adrenergic beta-Antagonists; Hemangioma, Capillary; Humans; Infant; Orbital Neoplasms; Propranolol | 2010 |
Everything old is new again.
Topics: Adrenergic beta-Antagonists; Hemangioma, Capillary; Humans; Orbital Neoplasms; Propranolol | 2010 |
Reduction in astigmatism using propranolol as first-line therapy for periocular capillary hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Astigmatism; Blood Pressure; Eyelid Neoplasms; Fe | 2011 |
[Successful treatment of orbital capillary hemangioma with propranolol].
Topics: Adrenergic beta-Antagonists; Biopsy; Exophthalmos; Female; Hemangioma, Capillary; Humans; Infant; Ma | 2011 |
Treatment of periocular infantile hemangiomas with propranolol: case series of 18 children.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Eyelid Neoplasms; Female; Follow-Up Studies; | 2011 |
Echographic evidence of regression of a periocular infantile capillary hemangioma treated with systemic propranolol.
Topics: Adrenergic beta-Antagonists; Eyelid Neoplasms; Female; Hemangioma, Capillary; Humans; Infant; Off-La | 2011 |
Oral propranolol for treatment of periocular infantile hemangiomas.
Topics: Administration, Oral; Antineoplastic Agents; Child, Preschool; Eyelid Neoplasms; Female; Hemangioma, | 2011 |
Colour Doppler ultrasound imaging findings in paediatric periocular and orbital haemangiomas.
Topics: Adrenergic beta-Antagonists; Blood Flow Velocity; Eyelid Neoplasms; Female; Follow-Up Studies; Gluco | 2012 |
Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment.
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents, Phytogenic; Disseminated Intravascular Coagulati | 2011 |
Successful first-line treatment with propranolol of multifocal infantile hepatic hemangioma with high-flow cardiac overload.
Topics: Dose-Response Relationship, Drug; Female; Hemangioma, Capillary; Humans; Infant; Liver; Liver Transp | 2011 |
Combined low-dose oral propranolol and oral prednisolone as first-line treatment in periocular infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Therapy, Combination; Eyelid Diseases; Femal | 2011 |
Preliminary experiences in treating infantile hemangioma with propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Administration Schedule; Female; Follow-Up S | 2014 |
Efficacy of systemic propranolol for severe infantile haemangioma of the orbit and eyelid: a case study of eight patients.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Eyelid Neoplasms; Follow-Up Stu | 2012 |
Refractive and structural changes in infantile periocular capillary haemangioma treated with propranolol.
Topics: Adrenergic beta-Antagonists; Eyelid Neoplasms; Female; Hemangioma, Capillary; Humans; Infant; Male; | 2011 |
Periocular lesion in an infant.
Topics: Adrenergic beta-Antagonists; Eyelid Neoplasms; Female; Hemangioma, Capillary; Humans; Infant; Laser | 2011 |
Successful treatment of orbital hemangioma with propranolol in a 5-year-old girl.
Topics: Child, Preschool; Female; Hemangioma, Capillary; Humans; Orbital Neoplasms; Propranolol | 2012 |
Reply to Spiteri Cornish and Reddy.
Topics: Antineoplastic Agents; Female; Hemangioma, Capillary; Humans; Male; Orbital Neoplasms; Propranolol | 2012 |
Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding?
Topics: Antineoplastic Agents; Female; Hemangioma, Capillary; Humans; Hyperkalemia; Hyperphosphatemia; Infan | 2012 |
Outpatient treatment of infantile hemangiomas with propranolol: a prospective study.
Topics: Ambulatory Care; Female; Hemangioma, Capillary; Humans; Infant; Male; Propranolol; Prospective Studi | 2012 |
High levels of β2-adrenoceptors are expressed in infantile capillary hemangiomas and may mediate the therapeutic effect of propranolol.
Topics: Adrenergic beta-Antagonists; Female; Gene Expression Regulation; Head and Neck Neoplasms; Hemangioma | 2012 |
Re: The use of propranolol in the management of periocular capillary haemangioma--a systematic review.
Topics: Antineoplastic Agents; Female; Hemangioma, Capillary; Humans; Male; Orbital Neoplasms; Propranolol | 2012 |
[A case of propranolol therapy for infantile capillary hemangiomas of the parotis].
Topics: Adrenergic beta-Antagonists; Female; Head and Neck Neoplasms; Hemangioma, Capillary; Humans; Infant; | 2012 |
Oral propranolol for treating infantile hemangiomas: a case series of 57 patients.
Topics: Administration, Oral; Female; Hemangioma, Capillary; Humans; Infant; Male; Propranolol; Prospective | 2012 |
Treatment of infantile capillary hemangioma of the eyelid with systemic propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Child, Preschool; Eyelid Neoplasms; Female | 2013 |
Topical timolol maleate 0.5% for infantile capillary haemangioma of the eyelid.
Topics: Adrenergic beta-Antagonists; Eyelid Neoplasms; Hemangioma, Capillary; Humans; Orbital Neoplasms; Pro | 2012 |
[Propranolol: Treatment of capillary hemangioma with orbital involvement].
Topics: Disease Progression; Eyelid Neoplasms; Facial Neoplasms; Female; Hemangioma, Capillary; Humans; Infa | 2012 |
Capillary haemangioma successfully treated with oral beta-blocker in Dar es Salaam, Tanzania: a case report.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Amblyopia; Facial Neoplasms; Female; Hemangioma, | 2013 |